Scholars@Duke
James Abbruzzese

James Abbruzzese

D.C.I. Distinguished Professor Emeritus of Medical Oncology
Medicine, Medical Oncology
james.abbruzzese@duke.edu
440 Mudd Building, Box 3406, Durham, NC 27710
440 Mudd Building, Box 3406, Durham, NC 27710

Selected Publications

Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.

Conference Ann Surg Oncol · November 20, 2024 BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ... Full text Link to item Cite

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.

Journal Article Gynecol Oncol · August 2024 OBJECTIVE: Combination cediranib/olaparib has reported activity in relapsed ovarian cancer. This phase 2 trial investigated the activity of cediranib/olaparib in relapsed ovarian cancer and its association with homologous recombination deficiency (HRD). ME ... Full text Link to item Cite

Cancer in 2023

Journal Article Cancer Discovery · December 12, 2023 Summary:Excerpts from the 13th edition of the annual AACR Cancer Progress Report (https://cancerprogressreport.aacr.org/progress/) to U.S. Congress and the public highlight cu ... Full text Cite

A Year of Advances in Precision Therapy for Blood Cancers

Journal Article Blood Cancer Discovery · November 1, 2023 Summary:Recent advances in precision therapies of blood cancers are highlighted here, adapted from the 13th edition of the annual AACR Cancer Progress Report (https://cancerpr ... Full text Cite

A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.

Journal Article Int J Gynecol Cancer · August 7, 2023 OBJECTIVE: Wee1 kinase is a crucial regulator of the G2/M checkpoint which prevents entry of damaged DNA into mitosis. Adavosertib (AZD1775), a selective inhibitor of Wee1, induces G2 escape and increases cytotoxicity when combined with DNA damaging agents ... Full text Link to item Cite

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma.

Journal Article Cancers (Basel) · May 31, 2022 KRAS mutations are prevalent in patients with pancreatic ductal adenocarcinoma (PDAC) and are critical to fostering tumor growth in part by aberrantly rewiring glucose, amino acid, and lipid metabolism. Obesity is a modifiable risk factor for pancreatic ca ... Full text Open Access Link to item Cite

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

Journal Article Lancet Oncol · February 2022 BACKGROUND: Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential be ... Full text Link to item Cite

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2671 Background: MERTK is a receptor tyrosine kinase from the tumor-associated macrophage kinase (TAMK) family that regulates key aspects of immune homeostasis and responses to infection. MERTK inhibition may lower the thresho ... Full text Cite

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).

Journal Article Melanoma Res · April 1, 2021 BACKGROUND: IL-2 inducible kinase (ITK) is highly expressed in metastatic melanomas and its inhibition suppresses melanoma cell proliferation. We hypothesize that ibrutinib has a direct antitumor effect in melanoma cell lines and that treatment of metastat ... Full text Link to item Cite

Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.

Journal Article Cell Death Dis · February 16, 2021 Oncogenic RAS is a critical driver for the initiation and progression of several types of cancers. However, effective therapeutic strategies by targeting RAS, in particular RASG12D and RASG12V, and associated downstream pathways have been so far unsuccessf ... Full text Link to item Cite

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity.

Journal Article Cancers (Basel) · February 13, 2021 Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) mutations have been considered a critical driver of PDAC initiation and progression. However, the effects of mutant KRAS ... Full text Link to item Cite

A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis.

Journal Article AME case reports · January 2021 Pancreatic adenocarcinoma commonly presents as metastatic disease and harbors a dire prognosis due to its aggressive behavior, propensity for resistance to therapies, and lack of targetable driver mutations. Additionally, despite advances in other cancers, ... Full text Cite

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.

Journal Article JCO precision oncology · January 2021 Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most appropriate ... Full text Cite

Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Journal Article HPB (Oxford) · November 2020 BACKGROUND: Adjuvant chemotherapy (AC) is associated with improved survival following resection of pancreatic adenocarcinoma but is frequently delayed or deferred due to perioperative complications or patient deconditioning. The aim of this study was to as ... Full text Link to item Cite

Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer.

Journal Article Mol Carcinog · August 2020 Because the peroxisome proliferator-activated receptor (PPAR) signaling pathway is involved in development and progression of pancreatic cancer, we investigated associations between genetic variants of the PPAR pathway genes and pancreatic cancer risk by u ... Full text Open Access Link to item Cite

Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

Conference Molecular Cancer Therapeutics · December 1, 2019 AbstractBackground: The combination of cediranib (ced) and olaparib (olap) improves progression-free survival and overall response rates (ORR) in women with recurrent plat sensitive high-grade serous (HGS) o ... Full text Cite

Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.

Journal Article Gastroenterology · November 2019 BACKGROUND & AIMS: Obesity is a risk factor for pancreatic cancer. In mice, a high-fat diet (HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic ductal adenocarcinoma (PDAC) by unknown mechanisms. We investigated how oncogenic ... Full text Link to item Cite

Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk.

Journal Article Mol Carcinog · August 2019 The liver kinase B1-AMP-activated protein kinase (LKB1-AMPK) pathway has been identified as a new target for cancer therapy, because it controls the glucose and lipid metabolism in response to alterations in nutrients and intracellular energy levels. In th ... Full text Open Access Link to item Cite

Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.

Journal Article Carcinogenesis · June 10, 2019 The AURORA pathway participates in mitosis and cell division, and alterations in mitosis and cell division can lead to carcinogenesis. Therefore, genetic variants in the AURORA pathway genes may be associated with susceptibility to pancreatic cancer. To te ... Full text Open Access Link to item Cite

Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk.

Journal Article Cancer Sci · June 2019 Pancreatic cancer (PanC) is one of the most lethal solid malignancies, and metastatic PanC is often present at the time of diagnosis. Although several high- and low-penetrance genes have been implicated in PanC, their roles in carcinogenesis remain only pa ... Full text Open Access Link to item Cite

Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS.

Journal Article Cell Commun Signal · February 28, 2019 Oncogenic KRAS plays a vital role in controlling tumor metabolism by enhancing aerobic glycolysis. Obesity driven by chronic consumption of high-fat diet (HFD) is a major risk factor for oncogenic KRAS-mediated pancreatic ductal adenocarcinoma (PDAC). Howe ... Full text Link to item Cite

Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells.

Journal Article Methods Mol Biol · 2019 Pancreatic cancer is a highly lethal disease and is projected to become the second leading cause of cancer-related death by 2020. Among the different subtypes, pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. The geneti ... Full text Link to item Cite

Carcinoma of Unknown Primary

Chapter · January 1, 2019 Carcinoma of unknown primary (CUP) is a diverse group of heterogeneous cancers presenting without a primary site and accounts for about 2% to 4% of all cancers. The past two decades have seen significant change in our approach to CUP patients. Therapy stra ... Full text Cite

Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development.

Journal Article Cancer Prev Res (Phila) · July 2018 Specificity protein (Sp) transcription factors (TFs) such as Sp1 are critical for early development but their expression decreases with age and there is evidence that transformation of normal cells to cancer cells is associated with upregulation of Sp1, Sp ... Full text Link to item Cite

Emerging therapeutic targets in pancreatic adenocarcinoma

Chapter · April 11, 2018 Pancreatic adenocarcinoma is one of the most lethal cancers but has limited therapeutic options necessitating continued investigation of new therapeutic agents. Recently, improved overall survival has been achieved with cytotoxic drug combinations includin ... Full text Cite

Preface

Book · April 11, 2018 Full text Cite

Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.

Journal Article Int J Cancer · April 1, 2018 The platelet-derived growth factor (PDGF) signaling pathway plays important roles in development and progression of human cancers. In our study, we aimed to identify genetic variants of the PDGF pathway genes associated with pancreatic cancer (PC) risk in ... Full text Open Access Link to item Cite

An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).

Journal Article Oncology · 2018 OBJECTIVES: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and di ... Full text Link to item Cite

The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Journal Article Pancreas · 2018 A workshop on "The Interface of Pancreatic Cancer with Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities" was held by the National Institute of Diabetes and Digestive and Kidney Diseases on October 12, 2017. The purpose of the workshop w ... Full text Link to item Cite

Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer.

Journal Article Diabetes · May 2017 The relationships between diabetes and pancreatic ductal adenocarcinoma (PDAC) are complex. Longstanding type 2 diabetes (T2DM) is a risk factor for pancreatic cancer, but increasing epidemiological data point to PDAC as also a cause of diabetes due to unk ... Full text Link to item Cite

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Journal Article J Natl Cancer Inst · April 2017 BACKGROUND: CA19-9, which is currently in clinical use as a pancreatic ductal adenocarcinoma (PDAC) biomarker, has limited performance in detecting early-stage disease. We and others have identified protein biomarker candidates that have the potential to c ... Full text Link to item Cite

Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.

Journal Article J Natl Cancer Inst · April 1, 2017 BACKGROUND: CA19-9, which is currently in clinical use as a pancreatic ductal adenocarcinoma (PDAC) biomarker, has limited performance in detecting early-stage disease. We and others have identified protein biomarker candidates that have the potential to c ... Full text Link to item Cite

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Journal Article J Gastrointest Surg · January 2017 BACKGROUND: The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) prior to pancreatoduodenectomy (PD). METHODS: Consecutive patients (622) wi ... Full text Link to item Cite

FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.

Journal Article Endocrinology · December 2016 The antiobese and antidiabetic fibroblast growth factor 21 (FGF21) regulates lipid metabolism and energy homeostasis by targeting the βKlotho-FGFR1 (fibroblast growth factor receptor 1) binary complex in adipose tissue adipocytes. Because lipid droplet is ... Full text Link to item Cite

Development of a Novel c-MET-Based CTC Detection Platform.

Journal Article Mol Cancer Res · June 2016 UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a fe ... Full text Open Access Link to item Cite

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

Journal Article Ann Oncol · June 2016 BACKGROUND: Incorporation of multiple enrichment biomarkers into prospective clinical trials is an active area of investigation, but the factors that determine clinical trial enrollment following a molecular prescreening program have not been assessed. PAT ... Full text Open Access Link to item Cite

The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer.

Journal Article Oncotarget · April 12, 2016 BACKGROUND: Curcumin is a natural product that is often explored by patients with cancer. Weight loss due to fat and muscle depletion is a hallmark of pancreatic cancer and is associated with worse outcomes. Studies of curcumin's effects on muscularity sho ... Full text Open Access Link to item Cite

RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.

Journal Article Int J Radiat Oncol Biol Phys · March 1, 2016 PURPOSE: To confirm whether a previously observed association between RECQ1 A159C variant and clinical outcome of resectable pancreatic cancer patients treated with preoperative chemoradiation is reproducible in another patient population prospectively tre ... Full text Link to item Cite

Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.

Journal Article J Oncol Pract · January 2016 Pancreatic cancer is a devastating disease with a universally poor prognosis. In 2015, it is estimated that there will be 48,960 new cases of pancreatic cancer and that 40,560 people will die of the disease. The 5-year survival rate is 7.2% for all patient ... Full text Open Access Link to item Cite

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Journal Article J Clin Oncol · November 1, 2015 PURPOSE: The decision by journals to append protocols to published reports of randomized trials was a landmark event in clinical trial reporting. However, limited information is available on how this initiative effected transparency and selective reporting ... Full text Link to item Cite

ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer.

Journal Article Cancer Med · November 2015 ABO blood type has previously been identified as a risk factor for thrombosis and pancreatic cancer (PC). The aim of the study is to demonstrate the associations between ABO blood type and other clinical factors with the risk of thromboembolism (TE) in pat ... Full text Link to item Cite

Molecular Therapeutics: Pancreatic Cancer

Chapter · October 30, 2015 As we learn more about the molecular underpinnings of pancreatic cancer, we are discovering new growth pathways that present opportunities for treatment. KRAS represents one such target. Activating mutations, found in the majority of pancreatic cancer, act ... Full text Cite

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.

Journal Article Cancer chemotherapy and pharmacology · September 2015 PurposeMetastatic pancreatic adenocarcinoma is considered a uniformly fatal disease with a median survival of 1 year with modern chemotherapy. While a subset of patients achieve prolonged survival, few of the factors that define this group of pati ... Full text Cite

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Journal Article Invest New Drugs · August 2015 BACKGROUND: Src has a critical role in tumor cell migration and invasion. Increased Src activity has been shown to correlate with disease progression and poor prognosis, suggesting Src could serve as a therapeutic target for kinase inhibition. Saracatinib ... Full text Link to item Cite

Abstract 891: FGF21 prevents high fat diet-induced pancreatic cancer in mice expressing oncogenic Kras

Conference Cancer Research · August 1, 2015 AbstractThe genetic landscape of pancreatic cancer shows nearly ubiquitous mutations of Kras. However, expression of mutant Kras alone is not sufficient to drive pancreatic ductal adenocarcinoma (PDAC) in ad ... Full text Cite

Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells.

Journal Article Mol Pharm · June 1, 2015 Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Cyclopamine (CPA), a potent inhibitor for sonic hedgehog pathway (SHH), shows great promises in PDAC treatment, including the disruption of tumor-associated stroma, and enhancement ... Full text Link to item Cite

Impacts of new-onset and long-term diabetes on clinical outcome of pancreatic cancer

Journal Article American Journal of Cancer Research · January 1, 2015 Patients with pancreatic cancer have a high frequency of concurrent diabetes. This study is aimed to demonstrate the impact of diabetes on clinical outcome of pancreatic cancer. Clinical and epidemiological information was collected from medical records or ... Cite

Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.

Journal Article Phys Biol · November 26, 2014 There is substantial heterogeneity in the clinical behavior of pancreatic cancer and in its response to therapy. Some of this variation may be due to differences in delivery of cytotoxic therapies between patients and within individual tumors. Indeed, in 1 ... Full text Link to item Cite

Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.

Journal Article Pathology · October 2014 Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with less than 5% five-year survival rate. Despite significant improvements in medical and surgical oncology and postoperative mortality rate, the overall survival for pat ... Full text Link to item Cite

Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Journal Article J Natl Cancer Inst · May 9, 2014 BACKGROUND: Child-Turcotte-Pugh (CTP) score is the standard tool to assess hepatic reserve in hepatocellular carcinoma (HCC), and CTP-A is the classic group for active therapy. However, CTP stratification accuracy has been questioned. We hypothesized that ... Full text Link to item Cite

Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.

Journal Article Hum Pathol · May 2014 Previous studies on the molecular alterations in ampullary adenocarcinoma (AA) are limited, and little is known about their clinical implications. The objective of this study is to examine the expression of p53, p21, cyclin D1, and Bcl2 and their clinical ... Full text Link to item Cite

Transport properties of pancreatic cancer describe gemcitabine delivery and response.

Journal Article J Clin Invest · April 2014 BACKGROUND: The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery of chemotherapy to cancer cells. We hypothesized that physical properties at vascular, extracellular, and cellular scales influence ... Full text Link to item Cite

SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.

Journal Article Hum Pathol · March 2014 Previous studies showed that SOX9 plays a critical role in pancreatic ductal development. The aim of this study was to evaluate SOX9 as a marker for pancreatic ductal lineage. SOX9 expression was evaluated by immunohistochemistry in 146 benign pancreas (BP ... Full text Link to item Cite

The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1.

Journal Article J Biol Chem · February 14, 2014 HPK1, a member of mammalian Ste20-like serine/threonine kinases, is lost in >95% pancreatic cancer through proteasome-mediated degradation. However, the mechanism of HPK1 loss has not been defined. The aims of this study are to identify the ubiquitin ligas ... Full text Link to item Cite

Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution.

Journal Article Am J Surg Pathol · February 2014 Although solid pseudopapillary neoplasms (SPNs) are considered tumors of low malignant potential, patients may present with aggressive disease (ie, liver metastasis/invasion into adjacent organs) and, rarely, die from disease. Although the clinicopathologi ... Full text Link to item Cite

Reassessing hepatocellular carcinoma staging in a changing patient population.

Journal Article Oncology · 2014 OBJECTIVE: Hepatocellular carcinoma (HCC) staging systems were developed using data predominantly from patients who had hepatitis and cirrhosis. Given the recent change in prevalence of viral hepatitis and cirrhosis at oncology centers, which has altered t ... Full text Link to item Cite

Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.

Journal Article J Gastrointest Surg · January 2014 Barriers to multimodality therapy (MMT) completion among patients with resectable pancreatic adenocarcinoma include early cancer progression and postoperative major complications (PMC). We sought to evaluate the influence of these factors on MMT completion ... Full text Link to item Cite

Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification.

Journal Article J Gastrointest Surg · January 2014 BACKGROUND: We previously described the clinical classification of patients with resectable pancreatic tumor anatomy but marginal performance status (PS) or reversible comorbidities as "borderline resectable type C" (BR-C). This study was designed to analy ... Full text Link to item Cite

Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Journal Article Journal of the National Cancer Institute · January 1, 2014 Child-Turcotte-Pugh (CTP) score is the standard tool to assess hepatic reserve in hepatocellular carcinoma (HCC), and CTP-A is the classic group for active therapy. However, CTP stratification accuracy has been questioned. We hypothesized that plasma insul ... Cite

Carcinoma of Unknown Primary

Chapter · January 1, 2014 Full text Cite

Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.

Journal Article Hum Pathol · December 2013 Because of the rarity of duodenal adenocarcinoma (DAC), the clinicopathologic features and prognostication data for DAC are limited. There are no published studies directly comparing the prognosis of DAC to that of ampullary adenocarcinoma (AA) and of panc ... Full text Link to item Cite

Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Journal Article Histopathology · December 2013 AIMS: To study the histological changes in non-neoplastic pancreas and the effects on pancreatic intraepithelial neoplasia (PanIN) after neoadjuvant chemoradiation therapy (NCRT) for pancreatic ductal adenocarcinoma (PDAC). METHODS AND RESULTS: We reviewed ... Full text Link to item Cite

The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.

Journal Article Ann Surg Oncol · December 2013 BACKGROUND: In treating pancreatic cancer, there is no clearly defined optimal sequence of chemotherapy, radiation therapy and surgery. Therefore, cost-effectiveness should be considered. The objective of this study was to compare cost and outcomes between ... Full text Link to item Cite

Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations.

Journal Article Cancer Metab · November 25, 2013 BACKGROUND: Endocrine FGF21 and FGF19 target adipocytes and hepatocytes through betaKlotho (KLB) and FGFR tyrosine kinases effecting glucose, lipid and energy metabolism. Both factors alleviate obesity and metabolic abnormalities which are contributing fac ... Full text Link to item Cite

The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.

Journal Article Arch Pathol Lab Med · November 2013 CONTEXT: Phosphatase and tensin homolog (PTEN) is one of the most frequently inactivated tumor suppressor genes in sporadic cancers. Somatic mutations of PTEN occur in many tumors including those of the gastrointestinal and hepatobiliary tracts. Loss of PT ... Full text Link to item Cite

Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction.

Journal Article Mol Carcinog · November 2013 Nonalcoholic fatty liver disease (NAFLD) is an emerging epidemic with high prevalence in Western countries. Genome-wide association studies had reported that a variation in the patatin-like phospholipase domain containing 3 (PNPLA3) gene is associated with ... Full text Link to item Cite

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.

Journal Article Invest New Drugs · October 2013 Metastatic pancreatic cancer carries a poor prognosis, with median survival on the order of several months. There is evidence that combining gemcitabine with either erlotinib or cisplatin may be superior to single agent gemcitabine in patients with good pe ... Full text Link to item Cite

Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.

Journal Article Cancer · September 15, 2013 BACKGROUND: The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepat ... Full text Link to item Cite

Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.

Journal Article Ann Surg Oncol · July 2013 BACKGROUND: Few data exist to guide oncologic surveillance following curative treatment of pancreatic cancer. We sought to identify a rational, cost-effective postoperative surveillance strategy. METHODS: We constructed a Markov model to compare the cost-e ... Full text Link to item Cite

Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.

Journal Article Hum Pathol · June 2013 Phosphatase and tensin homolog (PTEN) is a tumor suppressor in the AKT/mTOR pathway. Animal model studies have shown that loss of PTEN function is involved in the progression of pancreatic cancer. However, the prognostic significance of loss of PTEN expres ... Full text Link to item Cite

Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.

Journal Article Clin Cancer Res · February 1, 2013 PURPOSE: The most common genetic lesions in pancreatic ductal adenocarcinoma (PDAC) have been identified. However, significant gaps still exist in our understanding of how such genetic alterations act in concert to induce PDAC development. In this study, w ... Full text Link to item Cite

Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells.

Journal Article Histopathology · February 2013 AIMS: Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low-grade malignant neoplasm. To our knowledge, SPN with prominent atypical multinucleated giant tumour cells (MNGTCs) has not yet been reported. METHODS AND RESULTS: We identified four c ... Full text Link to item Cite

BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.

Journal Article Sci Signal · January 8, 2013 Phosphorylation and activation of Akt1 is a crucial signaling event that promotes adipogenesis. However, neither the complex multistep process that leads to activation of Akt1 through phosphorylation at Thr³⁰⁸ and Ser⁴⁷³ nor the mechanism by which Akt1 sti ... Full text Link to item Cite

Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.

Journal Article Oncology · 2013 OBJECTIVE: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of HCC. We report an analysis of the clinicopathologic features, treatment outcomes, and prognostic indicators of 94 cases. METHODS: We retrospectively collected clinicopathologic ... Full text Link to item Cite

The expression of pten is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy

Journal Article Archives of Pathology and Laboratory Medicine · January 1, 2013 Context.- Phosphatase and tensin homolog (PTEN) is one of the most frequently inactivated tumor suppressor genes in sporadic cancers. Somatic mutations of PTEN occur in many tumors including those of the gastrointestinal and hepatobiliary tracts. Loss of P ... Full text Cite

Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.

Journal Article PLoS One · 2013 BACKGROUND: Adenocarcinomas of the ampulla of Vater are classified as biliary cancers, though the exact epithelium of origin for these cancers is not known. We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas ... Full text Link to item Cite

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Journal Article J Clin Oncol · January 1, 2013 PURPOSE: Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use. METHODS: All therapeutic clinical trials in whic ... Full text Link to item Cite

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.

Journal Article Cancer · December 1, 2012 BACKGROUND: Experience with preoperative therapy for other cancers has led to an assumption that borderline resectable pancreatic cancers can be converted to resectable cancers with preoperative therapy. In this study, the authors sought to determine the r ... Full text Link to item Cite

Association of diabetes and perineural invasion in pancreatic cancer.

Journal Article Cancer Med · December 2012 Diabetes and perineural invasion are frequently observed in pancreatic cancer. In this study, we tested possible relations between diabetes and perineural invasion in patients with resected pancreatic cancer. We conducted a retrospective study in 544 cases ... Full text Link to item Cite

Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Journal Article Cancer Epidemiol Biomarkers Prev · August 2012 PURPOSE: Protein phosphatase 4 (PP4) has been reported to be overexpressed in breast and lung cancers. PP4 plays an important role in the regulation of centrosome maturation, DNA repair, NF-κB, and c-jun-NH(2)-kinase (JNK) signaling pathways. However, the ... Full text Link to item Cite

Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.

Journal Article Cancer · August 1, 2012 BACKGROUND: Studies have shown that superior mesenteric vein (SMV)/portal vein (PV) resection with pancreaticoduodenectomy (PD) is safe and feasible for patient with pancreatic adenocarcinoma (PAC). However, the prognostic significance of tumor involvement ... Full text Link to item Cite

Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.

Journal Article J Am Coll Surg · July 2012 BACKGROUND: Patients identified at surgical exploration with unresectable pancreatic ductal adenocarcinoma receive palliative, noncurative therapy. We hypothesized that accurate radiographic restaging, multimodality treatment, and advanced surgical techniq ... Full text Link to item Cite

Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Journal Article Cancer · June 15, 2012 BACKGROUND: Several grading schemes for the extent of residual tumor in posttreatment pancreaticoduodenectomy (PD) specimens have been proposed. However, the prognostic significance of these grading schemes is unknown. METHODS: Histopathologic slides of 22 ... Full text Link to item Cite

DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer.

Journal Article Mol Carcinog · June 2012 DNA repair plays a critical role in human cancers. We hypothesized that DNA mismatch repair gene variants are associated with risk of pancreatic cancer. We retrospectively genotyped 102 single-nucleotide polymorphisms (SNPs) of 13 mismatch repair related g ... Full text Link to item Cite

Metformin use is associated with better survival of diabetic patients with pancreatic cancer.

Journal Article Clin Cancer Res · May 15, 2012 PURPOSE: Accumulating evidence suggests that metformin has antitumor activity. The aim of this study was to determine whether metformin use has a survival benefit in patients with pancreatic cancer. EXPERIMENTAL DESIGN: We conducted a retrospective study o ... Full text Link to item Cite

A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease.

Journal Article Ann Surg Oncol · May 2012 BACKGROUND: Because of its rarity, adenocarcinoma of the small intestine is frequently compared to adenocarcinoma of the colon, although the validity of this comparison is not known. METHODS: Patients with small and large bowel adenocarcinoma (SBA and LBA) ... Full text Link to item Cite

Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

Journal Article J Thorac Oncol · May 2012 INTRODUCTION: The specific aims of the study were to evaluate the 2-year overall survival (OS) and progression-free survival (PFS), toxicity profile, and best objective response rate in patients with locally advanced, clinically unresectable esophageal can ... Full text Link to item Cite

A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.

Journal Article Anticancer Res · May 2012 BACKGROUND: The nucleoside 3'-c-ethynylcytidine (TAS-106) was designed to inhibit RNA synthesis which occurs throughout the cell cycle except for the M phase. TAS-106 is incorporated into cells, is rapidly phosphorylated to a monophosphate form, and is pre ... Link to item Cite

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Journal Article J Hematol Oncol · April 4, 2012 PURPOSE: Cell division cycle 20 (CDC20) homolog is an anaphase-promoting complex activator that is essential for cell division, but whether its expression in pancreatic ductal adenocarcinoma (PDAC) is significant is unknown. In this retrospective study, we ... Full text Link to item Cite

Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.

Journal Article Am J Surg Pathol · April 2012 Lymphovascular invasion (LVI) is a prognostic factor in many types of human malignancies, including pancreatic ductal adenocarcinoma (PDAC). However, the prognostic significance of LVI in patients with PDAC who have received neoadjuvant therapy and pancrea ... Full text Link to item Cite

Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer.

Journal Article Cancer Epidemiol · April 2012 OBJECTIVE: Insulin-like growth factor (IGF)-axis genes plays a critical role in cancer development and progression via their impact on the RAS/MAPK/ERK and PI3K/AKT/mTOR signaling pathways. We hypothesized that IGF-axis genetic variants modify individual s ... Full text Link to item Cite

Reply to A. Goyal et al

Journal Article Journal of Clinical Oncology · March 20, 2012 Full text Cite

Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.

Journal Article Am J Surg Pathol · March 2012 Perineural invasion (PNI) is one of the established prognostic factors in pancreatic ductal adenocarcinoma (PDAC). However, the prognostic significance of PNI in patients with PDAC who received neoadjuvant therapy and pancreaticoduodenectomy is not clear. ... Full text Link to item Cite

The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.

Journal Article Cancer Chemother Pharmacol · February 2012 PURPOSE: There are limited data regarding the role of second-line treatment for metastatic pancreatic cancer (mPC) after the failure of initial chemotherapy. No data exist on the use of GTX after the failure of first-line therapy. PATIENTS AND METHODS: We ... Full text Link to item Cite

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Journal Article Invest New Drugs · February 2012 BACKGROUND: TAS-106 is a novel nucleoside analog that inhibits RNA polymerases I, II and II and has demonstrated robust antitumor activity in a wide range of models of human cancer in preclinical studies. This study was performed to principally evaluate th ... Full text Link to item Cite

Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.

Journal Article Oncology · 2012 OBJECTIVE: A phase II study was performed to evaluate the efficacy and tolerability of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) patients, and to investigate clinical and molecular predictors of outcome. METHODS: 59 patients with ... Full text Link to item Cite

Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.

Journal Article Ann Diagn Pathol · January 2012 In patients with pancreatic ductal adenocarcinoma (PDA) who received neoadjuvant therapy and pancreatectomy, pathologic complete response (pCR) is rarely observed and the prognostic significance of pCR is not clear. In this study, we identified 11 patients ... Full text Link to item Cite

Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.

Journal Article J Gastrointest Surg · January 2012 OBJECTIVES: To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma. METHODS: One hundred ninety-four patients wi ... Full text Link to item Cite

Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Journal Article Cancer · January 1, 2012 BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancr ... Full text Link to item Cite

Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.

Journal Article Cancer Chemother Pharmacol · December 2011 PURPOSE: The gemcitabine and oxaliplatin (GEMOX) has yielded among the longest progression-free survival durations in patients with advanced pancreatic cancer (APC). We postulated that adding bevacizumab would increase the effectiveness of GEMOX. METHODS: ... Full text Link to item Cite

Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.

Journal Article Clin Cancer Res · November 15, 2011 PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death. No effective therapy is currently available for PDAC because of the lack of understanding of the mechanisms leading to its growth and development. Inflammatory c ... Full text Link to item Cite

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Journal Article J Clin Oncol · October 10, 2011 PURPOSE: Cirrhosis and hepatocellular carcinoma (HCC) together form a two-disease state that affects survival of patients with HCC and dictates treatment decisions and prognostic stratification of patients in clinical trials. The study objective was to imp ... Full text Link to item Cite

Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Journal Article Clin Cancer Res · September 1, 2011 PURPOSE: The resistance of tumors to antiangiogenic therapies is becoming increasingly relevant. There are currently no validated predictive biomarkers for selecting which cancer patients will benefit from antiangiogenic therapy. Also lacking are resistanc ... Full text Link to item Cite

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

Journal Article J Natl Cancer Inst · August 3, 2011 BACKGROUND: TGF-β-activated kinase-1 (TAK1), a mitogen-activated protein kinase kinase kinase, functions in the activation of nuclear factor κB (NF-κB) and activator protein-1, which can suppress proapoptotic signaling pathways and thus promote resistance ... Full text Link to item Cite

Introducing CCR perspectives in drug approval.

Journal Article Clin Cancer Res · August 1, 2011 Full text Link to item Cite

A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.

Journal Article Invest New Drugs · August 2011 BACKGROUND: The EGFR/Akt/NF-κB signalling pathway is frequently deregulated in pancreatic cancer and contributes to cell growth, metastasis and chemoresistance. An isoflavone, genistein, inactivates Akt and NF-κB and enhances the anti-tumor activity of erl ... Full text Link to item Cite

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Journal Article J Clin Oncol · August 1, 2011 PURPOSE: This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC). PATIENTS AND METHODS: Treatment- ... Full text Link to item Cite

Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer.

Journal Article Clin Cancer Res · July 1, 2011 PURPOSE: This study was designed to determine whether DNA methylation biomarkers are associated with recurrence and survival in colon cancer patients. EXPERIMENTAL DESIGN: A retrospective analysis of 82 patients who received curative surgical resection for ... Full text Link to item Cite

Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

Journal Article Clin Cancer Res · June 15, 2011 PURPOSE: Accurate identification of tissue of origin (ToO) for patients with carcinoma of unknown primary (CUP) may help customize therapy to the putative primary and thereby improve the clinical outcome. We prospectively studied the performance of a micro ... Full text Link to item Cite

V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.

Journal Article Cancer · June 1, 2011 BACKGROUND: Several staging systems have been proposed for hepatocellular carcinoma (HCC); however, none has incorporated circulating angiogenic biomarkers. The purpose of this study was to determine whether vascular endothelial growth factor (VEGF) could ... Full text Link to item Cite

Glucose metabolism gene variants modulate the risk of pancreatic cancer.

Journal Article Cancer Prev Res (Phila) · May 2011 Long-term type 2 diabetes is a known risk factor for pancreatic cancer (PC). We hypothesized that genetic variants in glucose metabolism modify individual susceptibility to PC, especially those associated with diabetes. We retrospectively genotyped 26 sing ... Full text Link to item Cite

Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · May 2011 BACKGROUND: The genetic factors predisposing individuals with obesity or diabetes to pancreatic cancer have not been identified. AIMS: To investigate the hypothesis that obesity- and diabetes-related genes modify the risk of pancreatic cancer. METHODS: We ... Full text Link to item Cite

Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals.

Journal Article Vaccine · April 5, 2011 Survivin is a universal tumor antigen that is being currently targeted in vaccine approaches against cancer. Our study here examined the immunogenicity of a novel variant of an HLA-A0201-binding decamer peptide from region 95 to 104 of Survivin (ELMLGEFLKL ... Full text Link to item Cite

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Journal Article Anticancer Res · April 2011 Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a ... Link to item Cite

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.

Journal Article Cancer Chemother Pharmacol · March 2011 PURPOSE: This study evaluated PX-12, a novel small molecule inhibitor of the proto-oncogene (Trx-1), in patients with previously treated advanced pancreatic cancer (APC). METHODS: PX-12 (54 or 128 mg/m²) was administered by 3-hour IV infusion daily × 5 day ... Full text Link to item Cite

Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.

Journal Article Cancer · February 15, 2011 BACKGROUND: The receptor tyrosine kinase Axl has been reported to be overexpressed in a variety of human cancers. Although previous studies have identified the role of Axl in the transformation, proliferation, survival, and invasion in cancers, the express ... Full text Link to item Cite

Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.

Journal Article Cancer · February 15, 2011 BACKGROUND: The purpose of this study was to identify single nucleotide polymorphisms (SNPs) of multidrug resistance genes that are associated with clinical outcome in patients with potentially resectable pancreatic adenocarcinoma who were treated with pre ... Full text Link to item Cite

Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer.

Journal Article Cancer · February 1, 2011 BACKGROUND: Altered glucose metabolism is the most common metabolic hallmark of malignancies. The authors tested the hypothesis that glucose metabolism gene variations affect clinical outcome in pancreatic cancer. METHODS: The authors retrospectively genot ... Full text Link to item Cite

Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid.

Journal Article Front Biosci (Schol Ed) · January 1, 2011 Non-steroidal anti-inflammatory drugs (NSAIDs) are primarily used for the treatment of acute or chronic conditions with pain and inflammation. Evidence from a wide range of sources suggested that chronic administration of NSAIDs reduced the risk of cancer ... Full text Link to item Cite

DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.

Journal Article Oncologist · 2011 PURPOSE: DNA mismatch repair (MMR) maintains genomic stability and mediates cellular response to DNA damage. We aim to demonstrate whether MMR genetic variants affect overall survival (OS) in pancreatic cancer. MATERIALS AND METHODS: Using the Sequenom met ... Full text Link to item Cite

I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Journal Article Oncology · 2011 OBJECTIVE: Improving the prognostic stratification of unresectable hepatocellular carcinoma (HCC) patients is critically needed. Since patients' survival is closely linked to the severity of the underlying liver disease, and insulin-like growth factor-1 (I ... Full text Link to item Cite

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Journal Article PLoS One · 2011 BACKGROUND: Multiple studies in recent years have identified highly tumorigenic populations of cells that drive tumor formation. These cancer stem cells (CSCs), or tumor-initiating cells (TICs), exhibit properties of normal stem cells and are associated wi ... Full text Link to item Cite

Therapeutic applications of NSAIDS in cancer: Special emphasis on tolfenamic acid

Journal Article Frontiers in Bioscience - Scholar · 2011 Non-steroidal anti-inflammatory drugs (NSAIDs) are primarily used for the treatment of acute or chronic conditions with pain and inflammation. Evidence from a wide range of sources suggested that chronic administration of NSAIDs reduced the risk of cancer ... Cite

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.

Journal Article Cancer · November 15, 2010 BACKGROUND: It has not been well established whether genetic variations can be biomarkers for clinical outcome of gemcitabine therapy. The purpose of this study was to identify single nucleotide polymorphisms (SNPs) of gemcitabine metabolic and transporter ... Full text Link to item Cite

Chemoprevention of pancreatic cancer: ready for the clinic?

Journal Article Cancer Prev Res (Phila) · November 2010 Advances in our molecular, clinical, and epidemiologic understanding of the risk and development of pancreatic cancer offer hope for preventing this disease, which is largely intractable once developed. This perspective on provocative, genetically engineer ... Full text Link to item Cite

New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.

Journal Article Clin Cancer Res · September 1, 2010 Pancreatic cancer (PC) is a highly lethal disease with complex etiology involving both environmental and genetic factors. Although cigarette smoking is known to explain 25% of cases, data from recent studies suggest that obesity and long-term type II diabe ... Full text Link to item Cite

Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment.

Journal Article Cytotherapy · September 2010 BACKGROUND AIMS: Because of the inflammatory nature and extensive stromal compartment in pancreatic tumors, we investigated the role of mesenchymal stromal cells (MSC) to engraft selectively in pancreatic carcinomas and serve as anti-tumor drug delivery ve ... Full text Link to item Cite

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Journal Article J Clin Oncol · August 1, 2010 PURPOSE: Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patie ... Full text Link to item Cite

Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.

Journal Article Gastroenterology · August 2010 BACKGROUND & AIMS: Insulin-like growth factor (IGF)-axis mediated signaling pathways play an important role in pancreatic cancer development and progression. We examined whether IGF-axis gene variants are associated with clinical outcomes in pancreatic can ... Full text Link to item Cite

High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Journal Article Clin Cancer Res · July 15, 2010 PURPOSE: Nucleolin is a major nucleolar protein that has been shown to be overexpressed in rapidly dividing cells and plays an essential role in cell proliferation and survival. However, the expression and significance of nucleolin in pancreatic ductal ade ... Full text Link to item Cite

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Journal Article BMC Cancer · July 14, 2010 BACKGROUND: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies suggest that prolonged ... Full text Link to item Cite

Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.

Journal Article Ann Surg Oncol · July 2010 PURPOSE: The role of carbohydrate antigen (CA) 19-9 in the evaluation of patients with resectable pancreatic cancer treated with neoadjuvant therapy prior to planned surgical resection is unknown. We evaluated CA 19-9 as a marker of therapeutic response, c ... Full text Link to item Cite

Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.

Journal Article Acta Oncol · May 2010 BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven. We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected smal ... Full text Link to item Cite

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Journal Article Cancer · April 15, 2010 BACKGROUND: Despite the observed association between diabetes mellitus and hepatocellular carcinoma (HCC), little is known about the effect of diabetes duration before HCC diagnosis and whether some diabetes medications reduced the risk of HCC development. ... Full text Link to item Cite

S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.

Journal Article Am J Clin Oncol · April 2010 OBJECTIVE: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting. METHODS: Patients w ... Full text Link to item Cite

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.

Journal Article Cancer · March 15, 2010 BACKGROUND: Docetaxel, cisplatin, and 5-flurouracil (DCF) administered every 3 weeks produces a high rate of treatment-related adverse events. The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF. ... Full text Link to item Cite

Introducing new strategies in..

Journal Article Clin Cancer Res · March 1, 2010 Full text Link to item Cite

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Journal Article J Clin Oncol · January 20, 2010 PURPOSE: We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines ... Full text Link to item Cite

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.

Journal Article Br J Cancer · January 5, 2010 BACKGROUND: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the development of adenocarcinoma. To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), w ... Full text Link to item Cite

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Journal Article Clin Cancer Res · January 1, 2010 PURPOSE: To show whether single nucleotide polymorphisms (SNP) of drug metabolic genes were associated with toxicity of 2',2'-difluoro 2'-deoxycytidine (gemcitabine)-based chemoradiotherapy and overall survival (OS) of patients with pancreatic cancer. EXPE ... Full text Link to item Cite

Barriers to integrating gene profiling for stage II colon cancer

Journal Article Clinical Cancer Research · December 15, 2009 The identification of high-risk subsets of colon cancers has undergone extensive study over the years, and multidimensional gene signatures have shown promise for colon cancer. However, several hurdles need to be overcome in order to show the benefit of th ... Full text Cite

Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.

Journal Article J Pain Symptom Manage · December 2009 We previously demonstrated that select cytokine gene polymorphisms in interleukin (IL)-8 are a significant predictor of pain and analgesia in patients with lung cancer. This study explores the role of 13 potentially functional polymorphisms in cytokine gen ... Full text Link to item Cite

Reply

Journal Article Hepatology · November 27, 2009 Full text Cite

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

Journal Article J Clin Oncol · November 20, 2009 Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross met ... Full text Link to item Cite

Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.

Journal Article Clin Cancer Res · October 15, 2009 PURPOSE: Development of novel agents and drug combinations are urgently needed for treatment of pancreatic cancer. Oxaliplatin belongs to an important class of DNA-damaging organoplatinum agents, useful in pancreatic cancer therapy. However, increased abil ... Full text Link to item Cite

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).

Journal Article Invest New Drugs · October 2009 INTRODUCTION: Patients with metastatic colorectal cancer who progress on standard chemotherapy have limited treatment options. New and effective drugs are needed for these patients. Romidepsin is a histone deacetylase inhibitor that can alter chromatin str ... Full text Link to item Cite

Antidiabetic therapies affect risk of pancreatic cancer.

Journal Article Gastroenterology · August 2009 BACKGROUND & AIMS: Antidiabetic drugs have been found to have various effects on cancer in experimental systems and in epidemiologic studies, although the association between these therapeutics and the risk of human pancreatic cancer has not been explored. ... Full text Link to item Cite

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Journal Article Cancer Res · July 15, 2009 A better understanding of drug resistance mechanisms is required to improve outcomes in patients with pancreatic cancer. Here, we characterized patterns of sensitivity and resistance to three conventional chemotherapeutic agents with divergent mechanisms o ... Full text Link to item Cite

Body mass index and risk, age of onset, and survival in patients with pancreatic cancer.

Journal Article JAMA · June 24, 2009 CONTEXT: Obesity has been implicated as a risk factor for pancreatic cancer. OBJECTIVE: To demonstrate the association of excess body weight across an age cohort and the risk, age of onset, and overall survival of patients with pancreatic cancer. DESIGN, S ... Full text Link to item Cite

Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Journal Article J Clin Oncol · June 1, 2009 PURPOSE: Adenocarcinomas of the small bowel and ampulla of Vater represent rare cancers that have limited data regarding first-line therapy. We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in pa ... Full text Link to item Cite

Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.

Journal Article Hepatology · May 2009 Thyroid hormones play an essential role in lipid mobilization, lipid degradation, and fatty acid oxidation. Hypothyroidism has been associated with nonalcoholic steatohepatitis; however, the association between thyroid diseases and hepatocellular carcinoma ... Full text Link to item Cite

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Journal Article Cancer Res · May 1, 2009 Chemotherapeutic regimens for the treatment of colorectal cancer generally include oxaliplatin, although inherent and acquired resistance is common. One potential mediator of oxaliplatin sensitivity is the nonreceptor protein tyrosine kinase, Src, the acti ... Full text Link to item Cite

Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism.

Journal Article Mol Cancer Res · May 2009 Activator protein-1 (AP-1) regulates the expression of several genes involved in human tumorigenesis. However, there is little known about this transcription factor in pancreatic ductal adenocarcinoma. We recently found high levels of AP-1-binding activiti ... Full text Link to item Cite

Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.

Conference Ann Surg Oncol · April 2009 INTRODUCTION: Actual 5-year survival rates of 10-18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of multimodality therapy was uncommon in these series. We evaluated long-term survival and patterns of recurrence ... Full text Link to item Cite

Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.

Journal Article J Clin Oncol · April 1, 2009 PURPOSE: DNA mismatch repair (MMR) is critical in maintaining genomic stability and may modulate the cellular response to gemcitabine. We hypothesized that genetic variations in MMR may affect the clinical outcome of patients with pancreatic cancer. PATIEN ... Full text Link to item Cite

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.

Journal Article Cancer Res · March 15, 2009 Despite rapid advances in many fronts, pancreatic cancer (PC) remains one of the most difficult human malignancies to treat due, in part, to de novo and acquired chemoresistance and radioresistance. Gemcitabine alone or in combination with other convention ... Full text Link to item Cite

Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.

Journal Article Mol Cancer Ther · March 2009 Survivin is overexpressed in most human cancers, including pancreatic adenocarcinoma. Expression of survivin is regulated by specificity protein (Sp) proteins and related to resistance to radiation therapy. Tolfenamic acid induces Sp protein degradation in ... Full text Link to item Cite

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

Journal Article J Clin Oncol · February 20, 2009 PURPOSE: The study objective was to determine the proportion of patients with hepatocellular carcinoma (HCC) treated with the combination of bevacizumab (B) and erlotinib (E) who were alive and progression free at 16 weeks (16-week progression-free surviva ... Full text Link to item Cite

Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells.

Journal Article Oncogene · February 5, 2009 There is emerging evidence that the oncogenic potential of hdm2 (human and/or murine double minute-2 protein) stems not only from its ability to counteract tumor suppressor p53 but also from its less understood p53-independent functions. Surprisingly, litt ... Full text Link to item Cite

Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.

Journal Article Cancer Res · February 1, 2009 Hematopoietic progenitor kinase 1 (HPK1) regulates stress responses, proliferation, and apoptosis in hematopoietic cells. In this study, we examined the expression, regulation, and functions of HPK1 in pancreatic ductal adenocarcinomas (PDA). We found that ... Full text Link to item Cite

In reply

Journal Article Journal of Clinical Oncology · February 1, 2009 Full text Cite

Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

Journal Article Ann Surg Oncol · February 2009 Genetic polymorphisms play an important role in clinical response to cytotoxic therapies. We hypothesized that polymorphisms in cell cycle genes may modulate response to preoperative chemoradiation and survival of pancreatic cancer patients. We evaluated 1 ... Full text Link to item Cite

The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States.

Journal Article J Hepatol · February 2009 BACKGROUND/AIMS: The study aimed at addressing the connection between positive family history of liver cancer and hepatocellular carcinoma (HCC) development in the USA. METHODS: At The University of Texas M.D. Anderson Cancer Center, 347 patients with path ... Full text Link to item Cite

DNA repair gene polymorphisms and risk of pancreatic cancer.

Journal Article Clin Cancer Res · January 15, 2009 PURPOSE: The current research was undertaken to examine the association between genetic variations in DNA repair and pancreatic cancer risk. EXPERIMENTAL DESIGN: We analyzed 9 single nucleotide polymorphisms of 7 DNA repair genes (LIG3, LIG4, OGG1, ATM, PO ... Full text Link to item Cite

Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study.

Journal Article J Comput Assist Tomogr · 2009 OBJECTIVES: To compare blood flow measurements of tumors assessed by perfusion computed tomography (pCT) and the clinical gold standard of 15O-labeled water positron emission tomography (15O-PET). METHODS: Blood flows were estimated by pCT (4-row multidete ... Full text Link to item Cite

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Journal Article Nat Protoc · 2009 For decades, xenografts using well-established human tumor cell lines have been the most commonly used models to study human cancers in mice. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evide ... Full text Link to item Cite

Highlights of the 2008 San Antonio Breast Cancer Symposium.

Conference Clin Adv Hematol Oncol · January 2009 Link to item Cite

Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer.

Journal Article Cancer Lett · December 8, 2008 p21 and p27, members of the kinase inhibitor protein (KIP) family, bind to cyclin-CDK complexes to inhibit their catalytic activity and induce cell cycle arrest. The purpose of our study was to identify whether the p21 (C-to-A), and p27 (T-to-G) polymorphi ... Full text Link to item Cite

Resected pancreatic cancer

Chapter · December 1, 2008 Pancreatic cancer is a systemic disease for most patients, and two-thirds of patients have locally advanced or metastatic disease at the time of diagnosis. For the subset of patients (20%) who present with potentially resectable tumors, the 5-year survival ... Full text Cite

Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · December 2008 Insulin-like growth factors (IGF) have been associated with risk of common human cancers, but the association between IGFs and pancreatic cancer risk is unclear. To determine whether genetic variations of IGF modify pancreatic cancer risk, we compared the ... Full text Link to item Cite

A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.

Journal Article J Cancer Res Clin Oncol · December 2008 PURPOSE: Preclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has anti-tumor activity in hepatocellular carcinoma (HCC). A phase I/II study was performed in advanced HCC patients (pts). PATIENT ... Full text Link to item Cite

Novel approaches to 'borderline resectable' pancreatic tumors.

Journal Article Oncology (Williston Park) · November 30, 2008 Link to item Cite

Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Journal Article Clin Cancer Res · November 1, 2008 PURPOSE: Mitogen-activated protein 4 kinase 4 (MAP4K4) is a serine/threonine kinase and belongs to the mammalian STE20/MAP4K family. Recent studies have shown that MAP4K4 is overexpressed in many types of human cancer and cancer cell lines. MAP4K4 plays an ... Full text Link to item Cite

Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.

Journal Article Cancer · October 15, 2008 BACKGROUND: Metastatic small bowel adenocarcinoma (SBA) has a poor prognosis. Because of the rarity of SBA, only a few studies have evaluated the role of chemotherapy in the treatment of metastatic SBA; thus, the benefit, if any, of adding a platinum compo ... Full text Link to item Cite

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Journal Article Cancer · October 15, 2008 BACKGROUND: To the authors' knowledge, there is no established second-line chemotherapy for patients with pancreatic cancer who have received gemcitabine-based therapy. A phase 2 trial was conducted to explore the efficacy of capecitabine and oxaliplatin ( ... Full text Link to item Cite

Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study.

Journal Article Int J Cancer · October 15, 2008 The International Agency for Research on Cancer has declared smoking to be a risk factor for hepatocellular carcinoma (HCC). However, passive exposure to cigarette smoke and use of noncigarette tobacco products on the risk of HCC has not been examined. The ... Full text Link to item Cite

Association between hepatitis B virus and pancreatic cancer.

Journal Article J Clin Oncol · October 1, 2008 PURPOSE: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are considered to be hepatotropic and are a major cause of hepatocellular carcinoma. However, little is known about the role of HBV and HCV infection in other malignancies. This study aimed to de ... Full text Link to item Cite

Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.

Journal Article Cancer Invest · October 2008 TAS-102 is a novel formulation of the fluorinated pyrimidine analogue trifluorothymidine (FTD) with an inhibitor of thymidine phosphorylase. The purpose of this study was to determine the MTD and DLT for TAS-102 administered three times a day on days 1-5 a ... Full text Link to item Cite

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

Journal Article Invest New Drugs · October 2008 This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors. Patients who met the eligibility ... Full text Link to item Cite

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

Journal Article J Clin Oncol · September 20, 2008 PURPOSE: To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site. PATIENTS AND METHODS: Diagnostic biopsy formalin-fixed, paraf ... Full text Link to item Cite

A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.

Journal Article Br J Cancer · September 2, 2008 Prolonged infusions have been shown to be safer and potentially more effective than bolus regimens of 5-fluorouracil (5-FU) as treatment for metastatic colorectal cancer (mCRC). However, infusional 5-FU requires central venous access and costly infusion pu ... Full text Link to item Cite

Knowledge of indications and utilization of EUS: a survey of oncologists in the United States.

Journal Article J Clin Gastroenterol · September 2008 BACKGROUND: Since its advent, endoscopic ultrasonography (EUS) has emerged as an invaluable tool in the diagnosis and management of gastrointestinal and adjacent cancers. Yet, it remains unclear how non-gastroenterologists who manage these malignancies use ... Full text Link to item Cite

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.

Journal Article Mol Carcinog · September 2008 Methylation of lysine 27 on histone H3 (H3K27) by the EZH2 complex is an epigenetic mark that mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis in both breast and prostate cancers. However, the status of H3K2 ... Full text Link to item Cite

Synergistic effects of multiple natural products in pancreatic cancer cells.

Journal Article Life Sci · August 15, 2008 Pancreatic cancer (PC) remains the fourth most common cause of cancer related death in the United States. Therefore, novel strategies for the prevention and treatment are urgently needed. Numerous dietary and pharmacological agents have been proposed as al ... Full text Link to item Cite

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.

Journal Article J Clin Oncol · July 20, 2008 PURPOSE: We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma. PATIENTS AND METHODS: Chemoth ... Full text Link to item Cite

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Journal Article J Clin Oncol · July 20, 2008 PURPOSE: We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. PATIENTS AND METHODS: Eligible patients with pan ... Full text Link to item Cite

Phase II trial of curcumin in patients with advanced pancreatic cancer.

Journal Article Clin Cancer Res · July 15, 2008 PURPOSE: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration-approved therapies for it, gemcitabine and erlotinib, produce objective responses in <10% of patients. We evaluated the clinical biological effects of curcum ... Full text Link to item Cite

Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.

Journal Article Lancet Oncol · June 2008 Carcinoma of unknown primary (CUP), which accounts for about 3-5% of all new cancers, is a challenging heterogeneous entity with an unmet research need. Traditionally, CUP has been managed with broad-spectrum chemotherapy, but with the increasing availabil ... Full text Link to item Cite

Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer.

Journal Article Carcinogenesis · June 2008 Aromatic amines, N-nitroso compounds and heterocyclic amines are suspected human pancreatic carcinogens. Cytochrome P450 (CYP) 1A2, N-acetyltransferase (NAT) 1, NAT2 and sulfotransferase (SULT) are enzymes involved in the metabolism of these carcinogens. T ... Full text Link to item Cite

Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer.

Journal Article Ann Surg Oncol · May 2008 BACKGROUND: The integration of biospecimens with reliable clinical data is critical to advance molecular findings from the laboratory to the clinic. We describe the development of an integrated pancreatic tissue bank (PTB) and clinical database for patient ... Full text Link to item Cite

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.

Journal Article J Clin Oncol · April 20, 2008 PURPOSE: The current strategy of drug development has been criticized as being highly inefficient. In 2004, the US Food and Drug Administration (FDA) released recommendations to improve this process, including a push for increased use of enrichment trials. ... Full text Link to item Cite

Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.

Journal Article Clin Cancer Res · April 1, 2008 PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) progresses rapidly and exhibits profound resistance to treatment. We recently reported that a great majority of PDAC tumors and tumor cell lines express elevated levels of tissue transglutaminase (TG2). Here ... Full text Link to item Cite

Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow.

Journal Article J Nucl Med · April 2008 UNLABELLED: PET molecular imaging of 15O-labeled water is the gold standard for measuring blood flow in humans. However, this requires an on-site cyclotron to produce the short-lived 15O tracer, which is cost-prohibitive for most clinical PET centers. The ... Full text Link to item Cite

Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.

Journal Article Clin Cancer Res · April 1, 2008 PURPOSE: The goals of this study were to determine if single-nucleotide polymorphisms in DNA damage repair genes and cell cycle regulating genes affect clinical response to combined gemcitabine radiation therapy and the overall survival (OS) of patients wi ... Full text Link to item Cite

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

Journal Article Mol Cancer Ther · April 2008 Most pancreatic cancer patients present with inoperable disease or develop metastases after surgery. Conventional therapies are usually ineffective in treating metastatic disease. It is evident that novel therapies remain to be developed. Transforming grow ... Full text Link to item Cite

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

Journal Article J Clin Oncol · March 10, 2008 PURPOSE: Effective systemic therapy for advanced carcinoid is lacking. The combination of bevacizumab (BEV) and pegylated (PEG) interferon alpha-2b was evaluated among patients with metastatic or unresectable carcinoid tumors. PATIENTS AND METHODS: Forty-f ... Full text Link to item Cite

XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer.

Journal Article Am J Gastroenterol · February 2008 OBJECTIVES: XRCC2 and XRCC3 are key components of the homologous recombination (HR) machinery that repairs DNA double-strand breaks. We hypothesized that the altered HR repair capacity conferred by single nucleotide polymorphisms (SNPs) would modify indivi ... Full text Link to item Cite

Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness

Journal Article Clinical Colorectal Cancer · January 1, 2008 Background: Improved survival of patients with metastatic colorectal cancer (CRC) has been shown to correlate with increased utilization of the 3 active cytotoxic chemotherapeutic agents: 5-fluorouracil (5-FU), irinotecan, and oxaliplatin, usually administ ... Full text Cite

Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.

Journal Article Cancer Res · December 1, 2007 Platelet-derived growth factor-D (PDGF-D) signaling plays critical roles in the pathogenesis and progression of human malignancies; however, the precise mechanism by which PDGF-D causes tumor cell invasion and angiogenesis remain unclear. Because Notch-1, ... Full text Link to item Cite

Risk factors for pancreatic cancer: case-control study.

Journal Article Am J Gastroenterol · December 2007 OBJECTIVES: Although cigarette smoking is the most well-established environmental risk factor for pancreatic cancer, the interaction between smoking and other risk factors has not been assessed. We evaluated the independent effects of multiple risk factors ... Full text Link to item Cite

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.

Journal Article Vaccine · November 14, 2007 We investigated the antitumor effect of survivin DNA vaccine in murine pancreatic and lymphoma models, and if xenogenic survivin can generate stronger immune response. We found that mice vaccinated with either human or mouse survivin DNA have significantly ... Full text Link to item Cite

Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · November 2007 We examined the association between N-acetyltransferase 1 and 2 (NAT1 and NAT2) haplotype and risk of pancreatic cancer by genotyping eight NAT1 and seven NAT2 single nucleotide polymorphisms in 532 patients and in 581 healthy controls (all non-Hispanic wh ... Full text Link to item Cite

'Unresectable' pancreatic cancer: Conceptual challenges

Journal Article ONCOLOGY · November 1, 2007 Cite

Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.

Journal Article Cancer Res · October 1, 2007 Aberrant epidermal growth factor receptor (EGFR) signaling is a major cause of tumor progression and metastasis; the underlying mechanisms, however, are not well understood. In particular, it remains elusive whether deregulated EGFR pathway is involved in ... Full text Link to item Cite

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

Journal Article Cancer · September 1, 2007 BACKGROUND: Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study wa ... Full text Link to item Cite

Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.

Journal Article J Pain Symptom Manage · September 2007 Pancreatic cancer is a lethal disease characterized by multiple disease-related symptoms. Chemoradiation therapy is a standard of treatment for locally advanced pancreatic cancer. Although shown to prolong survival, there is little information about treatm ... Full text Link to item Cite

Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.

Journal Article Carcinogenesis · August 2007 BACKGROUND: Variations in genetic mutations in pancreatic carcinoma between different geographical regions have not been studied extensively, especially in developing countries where pancreatic cancer is relatively rare. METHODS: We studied the molecular p ... Full text Link to item Cite

Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk.

Journal Article Pancreas · August 2007 OBJECTIVES: This study examined the epidemiology of pancreatic cancer in Egypt. METHODS: We obtained detailed information on smoking, occupational, medical, and reproductive histories from 194 pancreatic cancer cases and 194 controls. RESULTS: Compared wit ... Full text Link to item Cite

Establishment of three-dimensional cultures of human pancreatic duct epithelial cells.

Journal Article Biochem Biophys Res Commun · July 6, 2007 Three-dimensional (3D) cultures of epithelial cells offer singular advantages for studies of morphogenesis or the role of cancer genes in oncogenesis. In this study, as part of establishing a 3D culture system of pancreatic duct epithelial cells, we compar ... Full text Link to item Cite

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.

Journal Article Cancer · July 1, 2007 BACKGROUND: The current study was conducted to determine whether there were differences in outcome for patients with unresectable locally advanced pancreatic cancer (LAPC) who received treatment with chemoradiation therapy (CR) versus induction chemotherap ... Full text Link to item Cite

Phase I participants' views of quality of life and trial participation burdens.

Journal Article Support Care Cancer · July 2007 PURPOSE: Participants' perception of quality of life (QOL) and respondent burden have significant implications for investigators' ethical responsibilities to their subjects in phase I cancer trials. To address these responsibilities, analysis was conducted ... Full text Link to item Cite

Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models.

Journal Article Cancer Cell · July 2007 Pancreatic cancer is an aggressive malignancy with morbidity rates almost equal to mortality rates because of the current lack of effective treatment options. Here, we describe a targeted approach to treating pancreatic cancer with effective therapeutic ef ... Full text Link to item Cite

Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study.

Journal Article Cancer · June 15, 2007 BACKGROUND: The associations between passive smoking and the use of noncigarette tobacco products with pancreatic cancer are not clear. METHODS: In this case-control study, the authors collected information on passive smoking and the use of noncigarette to ... Full text Link to item Cite

Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.

Journal Article Cancer · May 15, 2007 BACKGROUND: Constitutive activation of nuclear factor-kappaB (NF-kappaB) is a frequent molecular alteration in pancreatic cancer and a number of studies have suggested that constitutive NF-kappaB activity plays a key role in the aggressive behavior of this ... Full text Link to item Cite

Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians.

Journal Article Clin Cancer Res · May 15, 2007 PURPOSE: Aurora-A and p16 play a major role in cell cycle checkpoint regulation. Both of them are important in the maintenance of centrosome duplication. Therefore, we hypothesized that polymorphisms in the two genes may interact or work together to influe ... Full text Link to item Cite

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Journal Article Mod Pathol · May 2007 Maspin (SERPINB5), a serine proteinase inhibitor, was first identified as a potential tumor suppressor on the basis of its differential expression between normal mammary epithelial cells and human breast carcinoma cell lines. Recent studies have shown that ... Full text Link to item Cite

HLA-A0201 positive pancreatic cell lines: new findings and discrepancies.

Journal Article Cancer Immunol Immunother · May 2007 Pancreatic cancer is being pursued as an immunotherapy target using antigen-specific vaccine approaches activating CD8(+) CTL and CD4(+) T-helper cells. CD8(+) CTL exert their anti-tumor effects in an HLA-restricted manner and only tumor cells carrying a m ... Full text Link to item Cite

Effects of base excision repair gene polymorphisms on pancreatic cancer survival.

Journal Article Int J Cancer · April 15, 2007 To explore the association between single nucleotide polymorphisms of DNA repair genes and overall survival of patients with pancreatic cancer, we conducted a study in 378 cases of pancreatic adenocarcinoma who were treated at The University of Texas M. D. ... Full text Link to item Cite

Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.

Journal Article Cancer Res · April 1, 2007 Vascular endothelial growth factor receptor-1 (VEGFR1) is expressed in cancer cell lines and tumors and, in pancreatic and colon cancer cells, activation of VEGFR1 is linked to increased tumor migration and invasiveness. Tolfenamic acid, a nonsteroidal ant ... Full text Link to item Cite

Dietary mutagen exposure and risk of pancreatic cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · April 2007 To investigate the association between dietary exposure to food mutagens and risk of pancreatic cancer, we conducted a hospital-based case-control study at the University of Texas M. D. Anderson Cancer Center during June 2002 to May 2006. A total of 626 ca ... Full text Link to item Cite

Polymorphisms of phase II xenobiotic-metabolizing and DNA repair genes and in vitro N-ethyl-N-nitrosourea-induced O6-ethylguanine levels in human lymphocytes.

Journal Article Mutat Res · March 5, 2007 This study tested the hypothesis that genetic variants of phase II detoxification enzymes and DNA repair proteins affect individual response to DNA damage from alkylating agents. In 171 healthy individuals, an immunoslot blot assay was used to measure O6-e ... Full text Link to item Cite

Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?

Journal Article J Am Coll Surg · March 2007 BACKGROUND: Delayed recovery after pancreaticoduodenectomy (PD) is believed to preclude adjuvant therapy for approximately 30% of patients who undergo elective PD as initial treatment for pancreatic adenocarcinoma. This study reexamined the frequency of de ... Full text Link to item Cite

Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer.

Journal Article Cancer · March 1, 2007 BACKGROUND: Pancreatic cancer is a multifactorial disease with metastasis-prone and therapy-resistant nature. The authors hypothesized that genetic variants of glutathione S-transferase (GST) affect detoxification of carcinogens and anticancer agents in th ... Full text Link to item Cite

In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer.

Journal Article Int J Cancer · February 15, 2007 We recently reported the potential of genistein in augmenting gemcitabine-induced killing of pancreatic cancer (Banerjee, S. et al., Cancer Research 2005;65:9064-72). Since cis-diaminedichloroplatinum (II) (cisplatin) is widely used against solid tumors, w ... Full text Link to item Cite

The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.

Journal Article Cancer Lett · January 8, 2007 We evaluated the association between the XPD exon 10 Asp(312)Asn and exon 23 Lys(751)Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analy ... Full text Link to item Cite

Clinical and in vitro studies of imatinib in advanced carcinoid tumors.

Journal Article Clin Cancer Res · January 1, 2007 PURPOSE: Effective systemic therapy options for carcinoid tumors are lacking. We conducted in vitro studies and a phase II clinical trial to explore the activity of imatinib in carcinoid tumors. EXPERIMENTAL DESIGN: Cells of the human bronchial carcinoid c ... Full text Link to item Cite

K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.

Journal Article Pancreas · January 2007 OBJECTIVES: To examine the profiles of K-ras mutations and p16 and preproenkephalin (ppENK) promoter hypermethylation and their associations with cigarette smoking in pancreatic cancer patients. METHODS: In plasma DNA of 83 patients with untreated primary ... Full text Link to item Cite

Antiangiogenic cancer therapy

Chapter · January 1, 2007 The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combinati ... Full text Cite

Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.

Journal Article Cancer · December 1, 2006 BACKGROUND: Although patients with locally advanced pancreatic cancer (LAPC) have an extremely poor prognosis, they are a heterogeneous group. Prognostic factors are inadequately defined for disease-free survival and overall survival in patients with LAPC ... Full text Link to item Cite

Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.

Journal Article Invest New Drugs · November 2006 From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401. Of these 65 patients, 57 ... Full text Link to item Cite

Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells.

Journal Article Clin Cancer Res · November 1, 2006 PURPOSE: To determine whether the synthetic microRNAs (miRNA) could effectively target tumor cells we designed several miRNA complementary to glioma-associated antigen-1 (Gli-1) mRNA and investigated their ability to inhibit tumor cell proliferation. The s ... Full text Link to item Cite

Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.

Journal Article Cancer Res · November 1, 2006 The epidermal growth factor receptor (EGFR) is a target of new therapies in most nonhematologic cancers. EGFR blockade alone may not be sufficient for the control of growth and invasion of human pancreas cancer because of the independent activation of Akt ... Full text Link to item Cite

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.

Journal Article Invest New Drugs · November 2006 PURPOSE: The purpose of this Phase II multi-institutional study was to define the efficacy and toxicity of ixabepilone in patients with advance pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients were required to have pancreatic adenocarcinoma and me ... Full text Link to item Cite

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.

Journal Article Radiat Oncol · October 24, 2006 We retrospectively evaluated acute toxicity in 88 patients that were treated with capecitabine and concurrent radiotherapy to the upper abdomen. These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) wit ... Full text Link to item Cite

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

Journal Article J Clin Oncol · October 20, 2006 PURPOSE: A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia and d ... Full text Link to item Cite

Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.

Journal Article Cancer · October 15, 2006 BACKGROUND: Imatinib has demonstrated marked clinical efficacy against gastrointestinal stromal tumor (GIST). Microarray technology, real-time polymerase chain reaction (PCR) validation, and fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging ... Full text Link to item Cite

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Journal Article Cancer · September 15, 2006 BACKGROUND: The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of al ... Full text Link to item Cite

Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients.

Journal Article Int J Cancer · September 15, 2006 Variations in genetic mutations in pancreatic carcinoma between different populations have not been studied extensively, especially in developing countries where pancreatic cancer is rare. We studied the molecular pathology of 44 pancreatic carcinomas from ... Full text Link to item Cite

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.

Journal Article Mol Cancer Ther · September 2006 Although it displays promising activity in other tumor models, the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on human pancreatic cancer cells have not been comprehensively explored. We report that a majority of human pancre ... Full text Link to item Cite

Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.

Journal Article Cancer Res · August 1, 2006 The epidermal growth factor receptor (EGFR) signaling network plays critical roles in human cancers, including pancreatic cancer, suggesting that the discovery of specific agents targeting EGFR would be extremely valuable for pancreatic cancer therapy. EGF ... Full text Link to item Cite

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Journal Article Ann Surg Oncol · August 2006 With recent advances in pancreatic imaging and surgical techniques, a distinct subset of pancreatic tumors is emerging that blurs the distinction between resectable and locally advanced disease: tumors of "borderline resectability." In our practice, patien ... Full text Link to item Cite

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.

Journal Article Invest New Drugs · July 2006 PURPOSE: The purpose of this Phase II multi-institutional trial was to determine the efficacy and toxicity of R115777 in previously untreated patients with metastatic colorectal carcinoma. PATIENTS AND METHODS: Patients were required to have histologically ... Full text Link to item Cite

Geographical clustering of pancreatic cancers in the Northeast Nile Delta region of Egypt.

Journal Article Arch Environ Contam Toxicol · July 2006 The northeast Nile Delta, Egypt's most polluted region, appears to have a high incidence of pancreatic cancer. We sought to determine whether there is any geographic clustering of pancreatic cancers there and, if so, whether such clustering might be associ ... Full text Link to item Cite

Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.

Journal Article J Natl Cancer Inst · June 21, 2006 BACKGROUND: Sp1, Sp3, and Sp4 are transcription factors that regulate cell proliferation and vascular endothelial growth factor (VEGF) expression and are overexpressed in many cancer cell lines. For some cancers, Sp1 overexpression is associated with poor ... Full text Link to item Cite

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Journal Article J Clin Oncol · June 1, 2006 PURPOSE: This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma. PATIENTS AND METH ... Full text Link to item Cite

Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant.

Journal Article Cancer Lett · May 8, 2006 Pancreatic cancer is highly aggressive with extremely poor prognosis. Developing a pancreatic cancer specific promoter (PCSP) is one approach for pancreatic cancer gene therapy. We have modified the promoter of cholecystokinin type A receptor (CCKAR), name ... Full text Link to item Cite

Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.

Journal Article J Clin Oncol · April 10, 2006 PURPOSE: Our goal was to determine whether single nucleotide polymorphisms (SNPs) in DNA repair genes influence the clinical outcome of pancreatic cancer. PATIENTS AND METHODS: We evaluated 13 SNPs of eight DNA damage response and repair genes in 92 patien ... Full text Link to item Cite

Metastatic patterns in adenocarcinoma.

Journal Article Cancer · April 1, 2006 BACKGROUND: Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports. The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcin ... Full text Link to item Cite

Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.

Journal Article Am J Clin Oncol · April 2006 OBJECTIVES: Metastatic esophageal carcinoma is an incurable disease with median survival duration of 6 to 8 months. Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patie ... Full text Link to item Cite

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Journal Article Cancer Res · April 1, 2006 The epidermal growth factor receptor (EGFR) is considered an important therapeutic target in pancreatic cancer, but it is currently impossible to identify those patients who are most likely to benefit from EGFR-directed therapy. We examined the biological ... Full text Link to item Cite

Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival.

Journal Article Ann Surg Oncol · April 2006 BACKGROUND: The natural history and prognosis for patients with intraductal papillary mucinous neoplasms (IPMN) with and without invasion remain poorly defined. This study evaluated the outcome after pancreatectomy for IPMN according to the pancreatic tran ... Full text Link to item Cite

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Journal Article Cancer Res · April 1, 2006 The proteasome inhibitor bortezomib (formerly known as PS-341) recently received Food and Drug Administration approval for the treatment of multiple myeloma, and its activity is currently being evaluated in solid tumors. Bortezomib triggers apoptosis in pa ... Full text Link to item Cite

Protein fragment domains identified using 2D gel electrophoresis/MALDI-TOF.

Journal Article J Biomol Tech · April 2006 We previously reported a protein expression profiling experiment conducted on human pancreatic tissues using 2D gel electrophoresis and mass spectrometry. Here, 18 spots that were identified in the gel at molecular weights more than 10 kDa lower than datab ... Link to item Cite

Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival.

Journal Article Cancer Res · March 15, 2006 Genetic variation in DNA repair may affect the clinical response to cytotoxic therapies. We investigated the effect of six single nucleotide polymorphisms of the RecQ1, RAD54L, XRCC2, and XRCC3 genes on overall survival of 378 patients with pancreatic aden ... Full text Link to item Cite

Introducing CCR practice of translational oncology

Journal Article Clinical Cancer Research · March 15, 2006 Full text Cite

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Journal Article Am J Pathol · March 2006 The nonreceptor protein tyrosine kinase Src is overexpressed in 70% of pancreatic adenocarcinomas. Here, we describe the effect of molecular and pharmacological down-regulation of Src on incidence, growth, and metastasis of pancreatic tumor cells in an ort ... Full text Link to item Cite

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

Journal Article J Clin Oncol · March 1, 2006 PURPOSE: To study the safety of bevacizumab with capecitabine-based chemoradiotherapy. PATIENTS AND METHODS: Patients with inoperable pancreatic adenocarcinoma received bevacizumab 2 weeks before radiotherapy (50.4 Gy treating the primary tumor and gross a ... Full text Link to item Cite

A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.

Journal Article Jpn J Clin Oncol · February 2006 BACKGROUND: One of the most studied pro-angiogenic factors involved in the development of colorectal cancer is the vascular endothelial growth factor (VEGF). The small molecule tyrosine kinase inhibitor semaxanib (SU5416) is one of the several agents targe ... Full text Link to item Cite

Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer.

Journal Article Cancer Res · January 15, 2006 The erbB family of receptor tyrosine kinases plays critical roles in human cancers, including pancreatic cancer. Discovering a specific agent, which targets multiple members of the erbB family, would be important in pancreatic cancer therapy. Recently, we ... Full text Link to item Cite

Selected polymorphisms of DNA repair genes and risk of pancreatic cancer.

Journal Article Cancer Detect Prev · 2006 BACKGROUND: Genetic variants of DNA repair genes may contribute to pancreatic carcinogenesis. O(6)-methylguanine-DNA methyltransferase (MGMT) is the major protein that removes alkylating DNA adducts, and apurinic/apyrimidinic endonuclease 1 (APE1) and X-ra ... Full text Link to item Cite

Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt.

Journal Article Environ Health Perspect · January 2006 UNLABELLED: The northeast Nile Delta region exhibits a high incidence of early-onset pancreatic cancer. It is well documented that this region has one of the highest levels of pollution in Egypt. Epidemiologic studies have suggested that cadmium, a prevale ... Full text Link to item Cite

Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates.

Journal Article Cancer Detect Prev · 2006 OBJECTIVES: Little is known about the descriptive epidemiology of pancreatic cancer in many developing countries, such as Egypt. It is believed to be rare in developing countries, but this may reflect lack of systematic cancer registration. Mortality may s ... Full text Link to item Cite

Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.

Journal Article Drugs · 2006 Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment. However, the efficacy of chemotherapy is limited. Gemcitabine is the only agent that improves sympt ... Full text Link to item Cite

Detection of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)-DNA adducts in human pancreatic tissues.

Journal Article Biomarkers · 2006 Recent epidemiological investigations have observed an association between the consumption of grilled or barbecued meat and an increased risk of pancreatic cancer, suggesting that dietary exposure to heterocyclic aromatic amines (HCA) may contribute to the ... Full text Link to item Cite

Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Journal Article Carcinogenesis · January 2006 To test the hypothesis that genetic variation in the metabolism of tobacco carcinogens, such as aromatic amines (AA) and heterocyclic amines (HCA), contributes to pancreatic cancer, we have examined genetic polymorphisms of three key enzymes, i.e. cytochro ... Full text Link to item Cite

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.

Journal Article Cancer Res · December 15, 2005 Bortezomib (Velcade, formerly known as PS-341) is a boronic acid dipeptide derivative that is a selective and potent inhibitor of the proteasome. We hypothesized that proteasome inhibition would lead to an accumulation of misfolded proteins in the cell res ... Full text Link to item Cite

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

Journal Article Cancer Res · December 15, 2005 Bortezomib (PS-341, Velcade) is a potent and selective inhibitor of the proteasome that is currently under investigation for the treatment of solid malignancies. We have shown previously that bortezomib has activity in pancreatic cancer models and that the ... Full text Link to item Cite

Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

Journal Article Cancer Res · November 15, 2005 Although gemcitabine has been approved as the first-line chemotherapeutic reagent for pancreatic cancer, its response rate is low and average survival duration is still only marginal. Because epidermal growth factor receptor (EGFR), vascular endothelial gr ... Full text Link to item Cite

Opportunities for targeted therapies in hepatocellular carcinoma.

Journal Article J Clin Oncol · November 1, 2005 Hepatocellular cancer (HCC) is the fifth most common solid tumor worldwide, accounting for 500,000 new cases annually. Although less common in the United States, HCC is expected to increase in incidence over the next two decades largely because of the prev ... Full text Link to item Cite

Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.

Journal Article Int J Oncol · November 2005 We screened an orthotopic nude mouse model of human pancreatic cancer for candidate serum biomarkers and examined their presence in the plasma of pancreatic cancer patients. Nude mice were injected in the pancreas with L3.9pl human pancreatic cancer cells. ... Link to item Cite

The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells.

Journal Article J Histochem Cytochem · November 2005 Syntaxin 17 (STX17) is a divergent member of the syntaxin family of proteins first discovered by Scheller and colleagues in a yeast two-hybrid screen designed to identify novel mammalian SNAREs (soluble N-ethylmaleimide-sensitive factor-attachment protein ... Full text Link to item Cite

Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.

Journal Article J Clin Oncol · October 20, 2005 PURPOSE: Prostate growth and differentiation are under androgenic control, and prior studies suggested that tumors that develop in hypogonadal men are more aggressive. We examined whether prostate weight was associated with tumor grade, advanced disease, o ... Full text Link to item Cite

Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells.

Journal Article Cancer Res · October 15, 2005 Phosphoinositide 3-kinase (PI3K) is activated in pancreatic cancer cells and plays a central role in their proliferation, survival, and drug resistance. Although the mechanism is unclear, PI3K activation in these cells could be due to physical interaction ... Full text Link to item Cite

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.

Journal Article Invest New Drugs · October 2005 Ninety per cent of pancreatic adenocarcinomas (PC) contain mutations of the K-Ras proto-oncogene resulting in constitutively activated Ras protein. A critical step in Ras activation is farnesylation of Ras protein. Farnesyl transferase inhibitors are compo ... Full text Link to item Cite

Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Journal Article Cancer Res · October 1, 2005 Soy isoflavone genistein exhibits growth inhibitory activity against human pancreatic cancer cell lines. We previously reported the potential of genistein to augment chemotherapeutic response of pancreatic cancer cells in vitro. In the present study, we in ... Full text Link to item Cite

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.

Journal Article Invest New Drugs · October 2005 BACKGROUND: Pancreaticobiliary malignancies respond poorly to conventional chemotherapy, and novel agents are needed. Dolatstatin-10 is a potent antimitotic pentapeptide isolated from the marine mollusk Dolabella auricularia that inhibits microtubule assem ... Full text Link to item Cite

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Journal Article Br J Cancer · July 25, 2005 The use of serial serum measurements of the carbohydrate antigen 19-9 (CA19-9) to guide treatment decisions and serve as a surrogate end point in clinical trial design requires further validation. We investigated whether CA19-9 decline represents an accura ... Full text Link to item Cite

Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.

Journal Article Neoplasia · July 2005 Although gemcitabine has been accepted as the first-line chemotherapeutic reagent for advanced pancreatic cancer, improvement of response rate and survival is not sufficient and patients often develop resistance. We hypothesized that the inhibition of phos ... Full text Link to item Cite

Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin.

Journal Article Cancer · June 15, 2005 BACKGROUND: Pancreatic carcinoma exhibits a unique genetic profile of mutations that may play key roles in its progression to malignant phenotypes. Constitutive activation of transcription factor nuclear factor kappa B (NF-kappaB) is a frequent molecular a ... Full text Link to item Cite

A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.

Journal Article Cancer Chemother Pharmacol · June 2005 PURPOSE: To evaluate whether celecoxib alters the conversion of gemcitabine into its active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), in peripheral blood mononuclear cells (PBMCs). METHODS: Patients with advanced pancreatic cancer who had no ... Full text Link to item Cite

Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.

Journal Article Am J Clin Oncol · June 2005 Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate. We decided to compare retrospectively the outcomes of patients treated concurrently with 5-fluorouracil and either 30 Gy or ... Full text Link to item Cite

5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · June 2005 To test the hypothesis that 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms modify the risk of pancreatic cancer, we conducted a hospital-based, case-control study involving 347 patients with newly diagnosed pancreatic adenocarcinoma and 348 ... Full text Link to item Cite

The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.

Journal Article Biochem Biophys Res Commun · May 27, 2005 We present immunohistochemical evidence that the mTOR/p70s6k pathway is activated in pancreatic tumors and show that the mTOR inhibitor and rapamycin analog CCI-779 potently suppresses the proliferation of pancreatic cancer cells. Consistent with a recent ... Full text Link to item Cite

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.

Journal Article Cancer Res · May 1, 2005 We studied growth factors and their receptors in tumor cells and tumor-associated endothelial cells as the therapeutic targets in colon cancer. Immunohistochemical analysis of 13 surgical specimens of human colon adenocarcinoma revealed that both tumor cel ... Full text Link to item Cite

AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells.

Journal Article Cancer Genet Cytogenet · May 2005 To test the hypothesis that AURKA amplification contributes to pancreatic tumorigenesis by increasing centrosome abnormality and chromosome instability, the current study explored the associations between AURKA amplification, chromosome instability, centro ... Full text Link to item Cite

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.

Journal Article Cancer · February 15, 2005 BACKGROUND: The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. However, the abundant vascularity of HCC presents an attractive target for anti ... Full text Link to item Cite

Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins.

Journal Article Clin Cancer Res · February 1, 2005 Plasma protein profiling using separations coupled to matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) has great potential in translational research; it can be used for biomarker discovery and contribute to disease diagnosis and the ... Link to item Cite

Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.

Journal Article Clin Cancer Res · January 15, 2005 PURPOSE: Pancreatic adenocarcinoma is currently the fourth leading cause of cancer death in the United States, and most pancreatic cancers develop locally advanced disease or metastasis at the time of diagnosis. The mechanisms by which it invades and metas ... Link to item Cite

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Journal Article Clin Cancer Res · January 15, 2005 PURPOSE: To determine the effects of small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR)-2 (SU5416 and SU6668) on receptor phosphorylation in tumor xenografts and in paired tumor biopsies obtained in three clinical trials in pa ... Link to item Cite

Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting.

Journal Article Rapid Commun Mass Spectrom · 2005 A peptide targeting method has been developed for diagnostic protein discovery, which combines proteolytic digestion of fractionated plasma proteins and liquid chromatography coupled to electrospray time-of-flight mass spectrometry (LC/ESI-TOFMS) profiling ... Full text Link to item Cite

Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.

Journal Article J Proteome Res · 2005 The low molecular weight plasma proteome and its biological relevance are not well defined; therefore, experiments were conducted to directly sequence and identify peptides observed in plasma and serum protein profiles. Protein fractionation, matrix-assist ... Full text Link to item Cite

Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.

Journal Article Int J Gastrointest Cancer · 2005 BACKGROUND: Maspin is both overexpressed in tumors and inflammation, implicating a possible role in bridging inflammation and neoplasia. Idiopathic inflammatory bowel disease (IBD) and IBD-associated dysplasias and carcinomas represent a prototype for stud ... Full text Link to item Cite

Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation

Journal Article International Journal of Gastrointestinal Cancer · 2005 Background. Maspin is both overexpressed in tumors and inflammation, implicating a possible role in bridging inflammation and neoplasia. Idiopathic inflammatory bowel disease (IBD) and IBD-associated dysplasias and carcinomas represent a prototype for stud ... Cite

Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells

Journal Article Clinical Cancer Research · 2005 Purpose: Pancreatic adenocarcinoma is currently the fourth leading cause of cancer death in the United States, and most pancreatic cancers develop locally advanced disease or metastasis at the time of diagnosis. The mechanisms by which it invades and metas ... Cite

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668

Journal Article Clinical Cancer Research · 2005 Purpose: To determine the effects of small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR)-2 (SU5416 and SU6668) on receptor phosphorylation in tumor xenografts and in paired tumor biopsies obtained in three clinical trials in pa ... Cite

Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry.

Journal Article Cancer Res · December 15, 2004 Pancreatic cancer is a rapidly fatal disease, and there is an urgent need for early detection markers and novel therapeutic targets. The current study has used a proteomic approach of two-dimensional (2D) gel electrophoresis and mass spectrometry (MS) to i ... Full text Link to item Cite

Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.

Journal Article Cancer · December 15, 2004 BACKGROUND: Cytokines have been implicated in diverse processes that are relevant to pancreatic carcinoma, including cachexia, asthenia, and tumor growth. The objective of this study was to examine the association between serum levels of proinflammatory an ... Full text Link to item Cite

Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.

Journal Article Cancer · November 15, 2004 BACKGROUND: Pancreatic carcinoma is a lethal malignancy, with the best available therapeutic option-gemcitabine-yielding response rates of < 10%. Because nuclear factor-kappaB (NF-kappaB) has been determined to play a role in cell survival/proliferation in ... Full text Link to item Cite

The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.

Journal Article Oncogene · November 11, 2004 The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively ... Full text Link to item Cite

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Journal Article Invest New Drugs · November 2004 PURPOSE: The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced colorectal cancer. PATIENTS AND METHODS: Patients were required to ... Full text Link to item Cite

A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

Journal Article Invest New Drugs · November 2004 PURPOSE: To evaluate the biologic effects of SU6668 in patients with solid tumors using comprehensive measures of pharmacokinetics (PK), functional imaging, and tissue correlative studies. EXPERIMENTAL DESIGN: Eligible patients with tumors accessible for c ... Full text Link to item Cite

Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force.

Journal Article Surg Oncol Clin N Am · October 2004 This article summarizes the results of recent studies using newer agents, including farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, inhibitors of the epidermal growth factor pathway, antiangiogenic therapeutics by inhibition of vascul ... Full text Link to item Cite

Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts.

Journal Article Mol Imaging · October 2004 In vivo optical imaging is potentially useful for evaluating the presence of tumor markers that are targets of molecular medicine. Here we report the synthesis and characterization of integrin alphavbeta3-targeted peptide cyclo(Lys-Arg-Gly-Asp-Phe) [c(KRGD ... Full text Link to item Cite

Adjuvant therapy for pancreatic cancer: current status and future directions.

Journal Article Surg Oncol Clin N Am · October 2004 This article summarizes the important past and ongoing adjuvant therapy trials for pancreatic cancer. The recent developments in the fields of radiosensitization, chemotherapy, and molecular-targeted therapy are outlined. Finally, the future study strategi ... Full text Link to item Cite

The convergence of cancer prevention and therapy in early-phase clinical drug development.

Journal Article Cancer Cell · October 2004 After decades of separate but not equal drug development, prevention and therapy are beginning to converge at the level of early-phase clinical testing. This highly beneficial convergence is due to spectacular molecular advances in our understanding of neo ... Full text Link to item Cite

The treatment of colorectal carcinoma: standard chemotherapy and beyond.

Journal Article Clin Adv Hematol Oncol · September 2004 Significant advances in the management of colorectal cancer patients have occurred within the past 5 years. New cytotoxic agents as well as novel targeted therapies have notably prolonged the survival of colorectal cancer patients with advanced disease. So ... Link to item Cite

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

Journal Article J Clin Oncol · September 1, 2004 PURPOSE: To compare the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and leucovorin (LV) between Japanese patients and patients in the United States with previously untreated metastatic colorectal cancer. ... Full text Link to item Cite

NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.

Journal Article Mol Cell Biol · September 2004 Nuclear factor kappaB (NF-kappaB) and activator protein 1 (AP-1) transcription factors regulate many important biological and pathological processes. Activation of NF-kappaB is regulated by the inducible phosphorylation of NF-kappaB inhibitor IkappaB by Ik ... Full text Link to item Cite

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.

Journal Article Invest New Drugs · August 2004 BACKGROUND: Both irinotecan and oxaliplatin are active agents in the treatment of patients with metastatic colorectal cancer (MCC). There is a strong preclinical rationale for combining these two agents. We sought to determine the dose-limiting toxicity (D ... Full text Link to item Cite

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.

Journal Article Invest New Drugs · August 2004 PURPOSE: The purpose of this phase II multi-institutional study was to define the efficacy and toxicity of infusional 5-FU in combination with PALA and leucovorin in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients were required to ... Full text Link to item Cite

Overexpression of synuclein-gamma in pancreatic adenocarcinoma.

Journal Article Cancer · July 1, 2004 BACKGROUND: Currently, pancreatic adenocarcinoma is the fourth leading cause of cancer-related death in the United States. Despite the advances in pancreatic carcinoma research, patients with this devastating disease have a very poor prognosis. To identify ... Full text Link to item Cite

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.

Journal Article Cancer Res · July 1, 2004 Vascular endothelial growth factor (VEGF) is a key angiogenic factor in a variety of solid tumors, making it one of the most attractive therapeutic targets. VEGF promotes the proliferation, survival, and differentiation of vascular endothelial cells by sti ... Full text Link to item Cite

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Journal Article J Clin Oncol · July 1, 2004 PURPOSE: To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer. ... Full text Link to item Cite

Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.

Journal Article J Biol Chem · June 25, 2004 Both pro- and antiapoptotic activities of NF-kappaB transcription factor have been observed; however, less is known about the mechanism by which NF-kappaB induces apoptosis. To elucidate how NF-kappaB regulates proapoptotic signaling, we performed function ... Full text Link to item Cite

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.

Journal Article J Clin Oncol · June 1, 2004 PURPOSE: Capecitabine is an oral fluoropyrimidine converted to fluourouracil (FU) preferentially in tumor tissue. It has proven clinical activity against colorectal cancer when used as first-line therapy. The objectives of this study were to assess the saf ... Full text Link to item Cite

Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?

Journal Article Oncology (Williston Park) · May 2004 The treatment of colorectal cancer has undergone enormous changes in the past decade. From a disease with a single treatment option (ie, fluorouracil, a modestly effective drug), the treatment options have evolved to include at least five new classes of an ... Link to item Cite

Novel therapies for pancreatic adenocarcinoma.

Journal Article Curr Oncol Rep · May 2004 Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and m ... Full text Link to item Cite

Diagnostic strategies for unknown primary cancer.

Journal Article Cancer · May 1, 2004 Unknown primary cancer (UPC) is defined by the presence of metastatic disease for which a primary site is undetectable on presentation. Computed tomography scan of the body was performed routinely in search of the primary cancer and invasive procedures wer ... Full text Link to item Cite

Novel therapies for pancreatic adenocarcinoma.

Journal Article Curr Gastroenterol Rep · April 2004 Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and m ... Full text Link to item Cite

Chemotherapy and radiation of anal canal cancer: the first approach.

Journal Article Surg Oncol Clin N Am · April 2004 Since the late 1970's, increasing evidence from single-arm phase II studies has indicated that combined modality therapy yields a complete response rate of approximately 80-90% in most patients with squamous cell cancers of the anal canal. Surgery, most co ... Full text Link to item Cite

Pancreatic cancer.

Conference Lancet · March 27, 2004 Pancreatic cancer remains a major unsolved health problem, with conventional cancer treatments having little impact on disease course. Almost all patients who have pancreatic cancer develop metastases and die. The main risk factors are smoking, age, and so ... Full text Link to item Cite

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.

Journal Article Cancer Res · March 15, 2004 The aggressive biology of human pancreatic adenocarcinoma has been linked with overexpression of vascular endothelial growth factor (VEGF). Constitutive activation of the transcription factor Sp1 plays a critical role in VEGF overexpression. Recent studies ... Full text Link to item Cite

NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells

Journal Article International Journal of Cancer · January 10, 2004 The effect of blockade of NF-κB activity on human pancreatic cancer angiogenesis was determined in an orthotopic xenograft model. Highly metastatic L3.3 human pancreatic cancer cells, which expressed an elevated level of constitutive NF-κB activity, were t ... Full text Cite

Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V.

Journal Article J Nucl Med · January 2004 UNLABELLED: 99mTc-Labeled annexin V has been used for the imaging of tumor apoptosis induced by chemotherapy. However, owing to the short half-life of annexin V, multiple injections of the radiotracer are necessary to capture the peak apoptotic activity. I ... Link to item Cite

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.

Journal Article Invest New Drugs · January 2004 PURPOSE: Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with ... Full text Link to item Cite

Diagnostic protein discovery using proteolytic peptide targeting and identification.

Journal Article Rapid Commun Mass Spectrom · 2004 Plasma protein profiling with mass spectrometry is currently being evaluated as a diagnostic tool for cancer and other diseases. These experiments consist of three steps: plasma protein fractionation, analysis with matrix-assisted laser desorption/ionizati ... Full text Link to item Cite

Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.

Journal Article Clin Cancer Res · January 1, 2004 PURPOSE: In a recent study, we presented preliminary evidence for biological activity in a Phase I dose-finding study (15-600 mg/m(2)) of recombinant human endostatin in patients with refractory solid tumors. Here, we conducted additional biomarker analyse ... Full text Link to item Cite

A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer.

Journal Article Clin Exp Metastasis · 2004 Insulin-like growth factor I receptor (IGF-IR) is critical to cell survival and growth and altered IGF-IR expression is found in many human cancers. However, its expression and potential role in gastric cancer development and progression has not been explo ... Full text Link to item Cite

Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation.

Journal Article Mol Cell · November 2003 The transcription factor NF-kappaB regulates genes involved in innate and adaptive immune response, inflammation, apoptosis, and oncogenesis. Proinflammatory cytokines induce the activation of NF-kappaB in both transient and persistent phases. We investiga ... Full text Link to item Cite

Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers.

Journal Article Cancer Cell · October 2003 The hedgehog (Hh) signaling pathway plays many roles in invertebrate and vertebrate development. For example, specific inhibition of sonic Hh expression is critical during early stages of pancreas organogenesis, but an active Hh pathway appears to be requi ... Full text Link to item Cite

Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study.

Journal Article Ann Surg Oncol · October 2003 BACKGROUND: Colorectal adenomas are the usual precursors to carcinoma in sporadic and hereditary colorectal cancers (CRC). METHODS: A total of 220 CRC patients (stages 0, I, and II) were randomized prospectively in a double-blind pilot study of calcium che ... Full text Link to item Cite

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Journal Article J Clin Oncol · September 15, 2003 PURPOSE: To conduct a randomized phase II trial of dose-intense gemcitabine using a standard 30-minute infusion or the fixed dose rate (FDR) infusion (10 mg/m2/min) in patients with pancreatic adenocarcinoma. PATIENTS AND METHODS: In this prospective trial ... Full text Link to item Cite

Surrogate markers in antiangiogenesis clinical trials.

Journal Article Br J Cancer · July 7, 2003 Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to app ... Full text Link to item Cite

Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.

Journal Article Clin Cancer Res · June 2003 PURPOSE: 9-Aminocamptothecin colloidal dispersion (9-ACCD; NSC 603071) is a specific inhibitor of topoisomerase I that can be given p.o. This Phase I trial was conducted to determine the toxicity profile, maximal tolerated dose, and pharmacokinetics profil ... Link to item Cite

Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer.

Journal Article Am J Clin Oncol · April 2003 We examined the use of MGI-114 (6-hydroxymethyacylfulvene) for the treatment of patients with advanced colorectal carcinoma. Twenty-six patients were enrolled, with a median age of 60 years (range 41-75); 64% were male and all patients had a performance st ... Full text Link to item Cite

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Journal Article J Clin Oncol · April 1, 2003 PURPOSE: R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that is required for the function of p21(ras) and other proteins. Given that RAS mutations are ... Full text Link to item Cite

A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis.

Journal Article Oncogene · March 27, 2003 In the present study, a model system for studying the role of nitric oxide (NO) in tumor growth and metastasis was reported. Incubation of Panc02 murine pancreatic adenocarcinoma cells in vitro with cytokines and interferon led to heterogeneous expression ... Full text Link to item Cite

Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis.

Journal Article Oncogene · March 6, 2003 We have demonstrated that nuclear factor-kappa B (NF-kappa B) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelia ... Full text Link to item Cite

Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.

Journal Article Clin Cancer Res · March 2003 PURPOSE: Multiple chromosome abnormalities, including gain of chromosome20q, have been detected frequently in human pancreatic cancers. Overexpression of the STK15/BTAK/Aurora A gene located on chromosome 20q13, which encodes a centrosome-associated serine ... Link to item Cite

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Journal Article Clin Cancer Res · February 2003 PURPOSE: Localized pancreatic carcinoma is rarely resectable and is resistant to conventional therapies. ONYX-015 (dl1520) is an E1B-55kD gene-deleted replication-selective adenovirus that preferentially replicates in and kills malignant cells. Endoscopic ... Link to item Cite

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.

Journal Article Oncogene · January 23, 2003 Expression of vascular endothelial growth factor (VEGF), a key angiogenic protein, has been linked with pancreatic cancer progression. However, the molecular basis for VEGF overexpression remains unclear. Immunohistochemical studies have indicated that VEG ... Full text Link to item Cite

Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.

Journal Article J Immunother · 2003 Activated monocytes-macrophages may be associated with antitumor activity, and activation of these cells by certain cytokines, primarily interferon gamma (IFN-gamma), can be indicated by alterations in the concentrations of neopterin, nitrate, or tryptopha ... Full text Link to item Cite

Function of nuclear factor kappaB in pancreatic cancer metastasis.

Journal Article Clin Cancer Res · January 2003 PURPOSE: We seek to elucidate the role of constitutive nuclear factor kappaB (NFkappaB) activity in human pancreatic cancer cells. We have demonstrated that the transcription factor NFkappaB is activated constitutively in human pancreatic adenocarcinoma an ... Link to item Cite

Experimental animal models of pancreatic carcinogenesis and metastasis.

Journal Article Int J Gastrointest Cancer · 2003 Pancreatic cancer is a lethal disease characterized by early metastasis, local invasion, and resistance to conventional therapies. To understand its etiology and eventually make prevention of it possible and effective, appropriate carcinogenesis models wil ... Full text Link to item Cite

The challenge of pancreatic cancer.

Journal Article Int J Gastrointest Cancer · 2003 Full text Link to item Cite

Function of nuclear factor κB in pancreatic cancer metastasis

Journal Article Clinical Cancer Research · 2003 Purpose: We seek to elucidate the role of constitutive nuclear factor κB (NFκB) activity in human pancreatic cancer cells. We have demonstrated that the transcription factor NFκB is activated constitutively in human pancreatic adenocarcinoma and human panc ... Cite

Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

Journal Article Clin Cancer Res · December 2002 PURPOSE: The purpose is to determine dose-limiting toxicity, pharmacokinetics,pharmacodynamics, and immunobiology after i.p. injections of recombinant human IL-12 (rhIL-12). EXPERIMENTAL DESIGN: rhIL-12 was administered to 29 previously treated patients wi ... Link to item Cite

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

Journal Article Mol Cancer Ther · December 2002 Recent studies have shown that the transcription factor, nuclear factor kappaB (NF-kappaB), regulates critical survival pathways in a variety of different cell types, including human pancreatic cancer cells. The activation of NF-kappaB is controlled by pro ... Link to item Cite

Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.

Conference Semin Oncol · December 2002 Pancreatic cancer continues to be a challenging therapeutic problem, with approximately 28,000 deaths annually in the United States. Most studies of single-agent or combination chemotherapy in the treatment of patients with advanced adenocarcinoma of the p ... Full text Link to item Cite

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.

Journal Article Hepatology · November 2002 Risk factors associated with hepatocellular carcinoma (HCC) are well documented, but the synergisms between these risk factors are not well examined. We conducted a hospital-based, case-control study among 115 HCC patients and 230 non-liver cancer controls ... Full text Link to item Cite

Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.

Journal Article Invest New Drugs · November 2002 PURPOSE: To investigate the hypothesis that a systemic agent designed to inhibit dihydropyrimidine dehydrogenase (DPD), the first enzyme in the fluoropyrimidine degradative pathway, could improve the effective amount of 5-fluorouracil (5-FU) delivered to a ... Full text Link to item Cite

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

Journal Article Cancer Res · November 1, 2002 Replication-selective oncolytic adenoviruses are being developed for the treatment of cancer, but the safety and feasibility of repeated adenovirus delivery to tumors via the bloodstream was unknown, particularly in light of a patient death after hepatic a ... Link to item Cite

Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.

Journal Article Clin Cancer Res · November 2002 PURPOSE: The tumor suppressor gene Smad4/DPC4, a key transcription factorin transforming growth factor beta (TGF-beta) signaling cascades,is inactivated in 50% of pancreatic adenocarcinomas. We seek to determine the role of Smad4/DPC4 in the suppression of ... Link to item Cite

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.

Journal Article Ann Oncol · October 2002 BACKGROUND: Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU). Pretreatment with eniluracil significantly increases plasma half-life, plasma concentration and oral bioa ... Full text Link to item Cite

Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.

Journal Article Am J Clin Oncol · October 2002 Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We conducted a phase II study of dolastatin-10 in patients with advanced colorectal cancer and no p ... Full text Link to item Cite

Epidermal growth factor receptor-targeted therapy for pancreatic cancer.

Conference Semin Oncol · October 2002 Epidermal growth factor receptor (EGFR) plays an important role in tumor development and maintenance. It is a cell surface molecule that mediates signal transduction from the cell surface to cytoplasm. Elevated expression of EGFR or its ligand correlates w ... Full text Link to item Cite

The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.

Journal Article Oncogene · September 19, 2002 The Rel/NF-kappaB transcription factors play a key role in the regulation of apoptosis and in tumorigenesis by controlling the expressions of specific genes. To determine the role of the constitutive activity of RelA in tumorigenesis, we generated pancreat ... Full text Link to item Cite

Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial.

Journal Article J Clin Oncol · September 15, 2002 PURPOSE: To describe prospective participants' initial source of information about, understanding of, and motivation to participate in a phase I clinical trial of the antiangiogenesis agent human recombinant endostatin. PATIENTS AND METHODS: We surveyed 10 ... Full text Link to item Cite

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.

Journal Article J Clin Oncol · September 15, 2002 PURPOSE: Angiogenesis is a target for the treatment of cancer and other diseases, and its complex biology suggests that establishing the appropriate dose and schedule for antiangiogenic treatment will require extensive study. We present the initial results ... Full text Link to item Cite

Phase I study of recombinant human endostatin in patients with advanced solid tumors.

Journal Article J Clin Oncol · September 15, 2002 PURPOSE: Endostatin, a 20-kd fragment of collagen XVIII, is a potent inhibitor of angiogenesis. We evaluated recombinant human endostatin (rh-Endo) in a phase I trial designed to assess safety, pharmacokinetics, and serum markers of angiogenesis in patient ... Full text Link to item Cite

Cancer: Introduction

Conference Cancer · August 15, 2002 Full text Cite

New applications of gemcitabine and future directions in the management of pancreatic cancer.

Conference Cancer · August 15, 2002 Gemcitabine has been reported to be an active agent in pancreatic cancer. Recent applications have included the use of a fixed-dose rate regimen in patients with advanced pancreatic cancer based on the observation that deoxycytidine kinase is saturated at ... Full text Link to item Cite

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

Journal Article Mol Cancer Ther · July 2002 Farnesyl:protein transferase (FPTase) inhibitors were developed as anti-Ras drugs, but they fail to inhibit Ki-Ras activity because Ki-Ras can be modified by geranylgeranyl:protein transferase type-I (GGPTase-I). L-778,123, an inhibitor of FPTase and GGPTa ... Link to item Cite

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

Journal Article Gut · June 2002 BACKGROUND: Non-selective cyclooxygenase (COX) inhibitors (non-steroidal anti-inflammatory drugs) inhibit large bowel carcinogenesis in patients with familial adenomatous polyposis (FAP). Their role in the duodenum of these patients is less certain. The di ... Full text Link to item Cite

Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome.

Journal Article J Clin Oncol · May 15, 2002 PURPOSE: To evaluate the toxicity of a preoperative regimen of paclitaxel and concurrent external-beam radiation therapy, pancreaticoduodenectomy, and electron-beam intraoperative radiation therapy (EB-IORT) for patients with resectable pancreatic adenocar ... Full text Link to item Cite

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

Journal Article Int J Radiat Oncol Biol Phys · April 1, 2002 PURPOSE: To retrospectively compare the toxicity and efficacy of concurrent gemcitabine-based chemoradiation with that of concurrent 5-fluorouracil (5-FU)-based chemoradiation in patients with unresectable pancreatic cancer. PATIENTS AND METHODS: Between S ... Full text Link to item Cite

Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.

Journal Article Crit Rev Oncol Hematol · February 2002 High-dose chemotherapy has been advocated by some investigators as a means to circumvent drug resistance, thereby improving treatment results in patients with solid tumors. For patients with unknown primary tumors, this hypothesis has only recently undergo ... Full text Link to item Cite

DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer.

Journal Article Mutat Res · January 15, 2002 To test the hypothesis that carcinogen exposure and oxidative stress are involved in pancreatic carcinogenesis in susceptible individuals, aromatic DNA adducts and 8-hydroxyguanosine (8-OH-dG) were measured by (32)P-postlabeling and HPLC-EC, respectively, ... Full text Link to item Cite

Unusually high rate of young-onset pancreatic cancer in the East Nile Delta region of Egypt.

Journal Article Int J Gastrointest Cancer · 2002 BACKGROUND: Pancreatic cancer is predominantly a disorder of the elderly population in the United States. In Egypt, the disease has traditionally been considered rare, and there has not been a previous publication on its population-based incidence or age d ... Full text Link to item Cite

Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.

Journal Article Cancer Invest · 2002 In this study, we estimated the response rate, duration of response, and type, severity and reversibility of toxicities in patients with Stage IV adenocarcinoma of the pancreas treated with docetaxel. Twenty-one patients with locally advanced or metastatic ... Full text Link to item Cite

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

Journal Article Seminars in Oncology · 2002 Epidermal growth factor receptor (EGFR) plays an important role in tumor development and maintenance. It is a cell surface molecule that mediates signal transduction from the cell surface to cytoplasm. Elevated expression of EGFR or its ligand correlates w ... Cite

New applications of gemcitabine and future directions in the management of pancreatic cancer

Journal Article Cancer · 2002 Gemcitabine has been reported to be an active agent in pancreatic cancer. Recent applications have included the use of a fixed-dose rate regimen in patients with advanced pancreatic cancer based on the observation that deoxycytidine kinase is saturated at ... Cite

Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality

Journal Article Seminars in Oncology · 2002 Pancreatic cancer continues to be a challenging therapeutic problem, with approximately 28,000 deaths annually in the United States. Most studies of single-agent or combination chemotherapy in the treatment of patients with advanced adenocarcinoma of the p ... Cite

International Journal of Gastrointestinal Cancer: Letter from the editor

Journal Article International Journal of Gastrointestinal Cancer · December 1, 2001 Cite

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.

Journal Article Gene Ther · November 2001 Both replication-incompetent and replication-selective adenoviruses are being developed for the treatment of cancer and other diseases. Concerns have been raised about the safety of intra-vascular adenovirus administration following a patient death on a cl ... Full text Link to item Cite

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.

Journal Article Cancer · November 1, 2001 BACKGROUND: Thalidomide has been shown to have antiangiogenic effects in preclinical models as well as a significant antitumor effect in hematologic tumors such as multiple myeloma. The authors performed this Phase II study to determine the activity, toxic ... Full text Link to item Cite

Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma.

Journal Article Int J Oncol · October 2001 A histopathology study of 22 pancreatic adenocarcinoma cases revealed that 13 of the patients presented with hyperplastic lesions (atypical and non-atypical hyperplasia, mucous cell hypertrophy, focal epithelial hyperplasia, and ductal papillary hyperplasi ... Full text Link to item Cite

The latest approaches to pancreatic disease

Journal Article Patient Care · September 15, 2001 Severe abdominal pain can signal pancreatitis or pancreatic cancer. Both conditions call for prompt diagnoses, careful monitoring, and aggressive pain management. ... Cite

T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.

Journal Article Int J Radiat Oncol Biol Phys · September 1, 2001 PURPOSE: To analyze the overall pattern of treatment failure and sites of pelvic disease recurrence relative to the radiation fields used in treating patients with clinically staged T4 rectal cancer with preoperative chemoradiation followed by multiviscera ... Full text Link to item Cite

Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.

Journal Article Clin Cancer Res · August 2001 Gemcitabine has modest activity in the treatment of advanced pancreatic cancer and is a potent radiosensitizer. We conducted a Phase I trial to determine the maximum tolerated dose of weekly gemcitabine delivered concurrently with radiation therapy for the ... Link to item Cite

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

Journal Article Clin Cancer Res · July 2001 CD26 is a M(r) 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions. In this report, we show that binding of sol ... Link to item Cite

Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.

Journal Article Oncogene · June 21, 2001 The influence of acidosis on the expression of the vascular endothelial growth factor (VEGF) gene was determined. FG human pancreatic adenocarcinoma cells were incubated for various time periods in media at a physiologically relevant pH level (6.7-7.4). Th ... Full text Link to item Cite

Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.

Journal Article Semin Oncol · June 2001 We compared and evaluated available laboratory and clinical data on the use of concurrent gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and radiation in pancreatic cancer to provide guidance for subsequent prospective research initiatives. ... Full text Link to item Cite

Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.

Journal Article Cancer Res · May 15, 2001 Vascular endothelial growth factor (VEGF) is a key angiogenic molecule that plays an important role in the growth and metastasis of many types of human cancer, including pancreatic adenocarcinoma. In this study, we explored the regulation of VEGF in human ... Link to item Cite

Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.

Journal Article J Biol Chem · April 6, 2001 The phosphoinositide 3-kinase (PI 3-kinase) pathway has been implicated in the activation of the proinflammatory transcription factor nuclear factor kappaB (NFkappaB). To investigate the role of this pathway in NFkappaB activation, we employed mutated in m ... Full text Link to item Cite

Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer.

Journal Article Am J Clin Oncol · April 2001 The aim of this study was to determine if the response to preoperative radiation and chemotherapy with continuous infusion 5-fluorouracil (5-FU) was predictive for survival among patients with locally advanced rectal cancer. Preoperative chemoradiation (CT ... Full text Link to item Cite

Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.

Journal Article Curr Oncol Rep · March 2001 Most solid-tumor malignancies remain incurable. Novel agents that target and counteract biologic mechanisms are now being developed. It is hoped that these drugs will allow for more effective, less toxic cancer treatments and long-term maintenance approach ... Full text Link to item Cite

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Journal Article Ann Surg Oncol · March 2001 BACKGROUND: For patients with potentially resectable pancreatic cancer, the poor outcome associated with resection alone and the survival advantage demonstrated for combined-modality therapy have stimulated interest in preoperative chemoradiotherapy. The g ... Full text Link to item Cite

Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.

Journal Article Int J Radiat Oncol Biol Phys · January 1, 2001 PURPOSE: To assess pelvic chemoradiotherapy (CXRT) without colostomy as a component of the multidisciplinary management of patients presenting with metastatic rectal cancer. METHODS AND MATERIALS: Eighty patients with synchronous distant metastases from re ... Full text Link to item Cite

Mouse models of metastatic pancreatic adenocarcinoma.

Journal Article Int J Pancreatol · 2001 Pancreatic adenocarcinoma is a deadly disease. Its etiology is unknown, and metastatic disease kills the majority of patients who have it. Effective prevention is clearly the ultimate goal for eradicating this disease provided that the effects of environme ... Full text Link to item Cite

Editor's note

Journal Article International Journal of Pancreatology · January 1, 2001 Cite

Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma.

Journal Article Cancer Res · January 1, 2001 Previous studies have shown that enforced expression of IFN-beta suppressed tumor growth and metastasis. In this report, we determined whether the induction of nitric oxide synthase II (NOS II) gene is required for IFN-beta-mediated antitumor activity usin ... Link to item Cite

A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy.

Journal Article Int J Pancreatol · 2001 In this study, we report a metastatic model of Panc02 murine pancreatic adenocarcinoma. Parental Panc02 cells were orthotopically implanted into the pancreas of syngeneic C57BL/6 mice. Tumor cells were isolated from liver micrometastases 90 d after tumor i ... Full text Link to item Cite

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.

Journal Article Int J Pancreatol · 2001 BACKGROUND: Gemcitabine and radiotherapy are a potent combination. A clinical assessment of the therapeutic ratio for locally advanced pancreatic cancer patients has not yet been reported. AIM OF STUDY: To assess the toxicity, survival, and pattern of fail ... Full text Link to item Cite

Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index

Journal Article Seminars in Oncology · 2001 We compared and evaluated available laboratory and clinical data on the use of concurrent gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and radiation in pancreatic cancer to provide guidance for subsequent prospective research initiatives. ... Cite

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer

Journal Article International Journal of Pancreatology · 2001 Background. Gemcitabine and radiotherapy are a potent combination. A clinical assessment of the therapeutic ratio for locally advanced pancreatic cancer patients has not yet been reported. Aim of Study. To assess the toxicity, survival, and pattern of fail ... Cite

Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.

Journal Article Am J Clin Oncol · December 2000 In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy for metastatic colorectal cancer. The drug was given by intravenous infusion at a dose of 700 mg/m ... Full text Link to item Cite

Patients' perceptions of a high-profile phase 1 trial.

Journal Article CLINICAL CANCER RESEARCH · November 1, 2000 Link to item Cite

Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma.

Journal Article J Interferon Cytokine Res · November 2000 Recent studies have shown that interleukin-8 (IL-8) plays an important role in the growth and metastasis of human pancreatic cancer. In the present study, we determined the molecular regulation of constitutive IL-8 expression in human pancreatic cancer cel ... Full text Link to item Cite

Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells.

Journal Article J Interferon Cytokine Res · November 2000 The role of cellular pH in the expression and regulation of interleukin-8 (IL-8) in human tumor cell lines was determined. Transient exposure to pH ranging from 7.4 to 6.7 induced pH-dependent expression of IL-8 at both the mRNA and protein levels in three ... Full text Link to item Cite

Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer.

Journal Article J Clin Oncol · October 15, 2000 PURPOSE: Preoperative combined-modality therapy for rectal cancer may allow for sphincter preservation, while decreasing recurrence rates and improving the overall prognosis. Oral chemotherapy with uracil and tegafur (UFT) plus leucovorin (LV) may reduce c ... Full text Link to item Cite

The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration.

Journal Article Int J Oncol · August 2000 Telomerase activation in differentiated cells is associated with cell immortalization. Detection of telomerase expression in cancer provides a potential biomarker to be evaluated in the diagnosis and prognosis of cancer patients. Analysis of telomerase act ... Full text Link to item Cite

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

Journal Article N Engl J Med · June 29, 2000 BACKGROUND: Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibition of cyclooxygenase-2. METHOD ... Full text Link to item Cite

Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.

Journal Article Int J Radiat Oncol Biol Phys · June 1, 2000 RATIONALE: To evaluate the response to a concomitant boost given during standard chemoradiation for locally advanced rectal cancer. METHODS AND MATERIALS: Concomitant boost radiotherapy was administered preoperatively to 45 patients with locally advanced r ... Full text Link to item Cite

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

Journal Article Cancer Res · June 1, 2000 We determined whether down-regulation of the epidermal growth factor-receptor (EGF-R) signaling pathway by oral administration of a novel EGF-R tyrosine kinase inhibitor (PKI166) alone or in combination with gemcitabine (administered i.p.) can inhibit grow ... Link to item Cite

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Journal Article Clin Cancer Res · May 2000 Both epidermal growth factor receptor (EGF-R) signaling mechanisms and angiogenesis have been evaluated as independent targets for therapy of human pancreatic carcinoma, but a link between the two processes has been identified only recently. This study eva ... Link to item Cite

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

Journal Article Clin Cancer Res · April 2000 Dolastatin (DOLA)-10 is a pentapeptide isolated from the mollusc Dolabella auricularia with clinically promising antitumor activity documented in various in vitro and in vivo tumor models. The objectives of this Phase I study were to determine the maximum ... Link to item Cite

Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.

Journal Article J Clin Oncol · February 2000 PURPOSE: A recent multicenter study of preoperative chemoradiation and pancreaticoduodenectomy for localized pancreatic adenocarcinoma suggested that biliary stent-related complications are frequent and severe and may prevent the delivery of all components ... Full text Link to item Cite

Current approaches and future strategies for pancreatic carcinoma.

Journal Article Invest New Drugs · February 2000 Pancreatic cancer is a lethal disease characterized by local invasion and early dissemination. It is resistant to conventional surgical, radiotherapeutic, and chemotherapeutic modalities. These interventions have had minimal impact on overall survival with ... Full text Link to item Cite

A multispecialty approach to the diagnosis and management of pancreatic cancer.

Journal Article Am J Gastroenterol · January 2000 This article reviews recent developments in pancreatic cancer research and offers a multispecialty perspective on the diagnosis and management of this challenging disease. Current findings in the molecular biology of the disease and their implications for ... Full text Link to item Cite

First pass FDG measured blood flow in tumors: A comparison with O-15 labeled water measured blood flow

Journal Article Clinical Positron Imaging (Netherlands) · January 1, 2000 The purpose of this study was to determine if the first-pass of FDG can be used to measure regional blood flow in tumors in the absence of perfusion imaging with a known blood flow tracer. PET scans were obtained in patients being evaluated for tumor perfu ... Full text Cite

Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors

Journal Article Clinical Positron Imaging (Netherlands) · January 1, 2000 Endostatin is a novel antiangiogenic agent currently in phase I trials. In the context of this trial, we are evaluating the use of non-invasive imaging with PET to determine the relationship between tumor blood flow and glucose metabolism in imaged tumors ... Full text Cite

Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia.

Journal Article J Interferon Cytokine Res · December 1999 The expression of interleukin-8 (IL-8) has been shown to play an important role in the growth and metastasis of human pancreatic cancer. In the present study, we investigated the regulation of IL-8 gene expression by hypoxic environments. Exposure of the h ... Full text Link to item Cite

Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic.

Journal Article Clin Cancer Res · November 1999 The role and regulation of interleukin 8 (IL-8) in the growth and metastasis of SG, FG, and L3.3 variants derived from COLO 357 human pancreatic cancer cells were determined. After orthotopic implantation in the pancreas of nude mice, SG cells produced the ... Link to item Cite

Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.

Journal Article Clin Cancer Res · November 1999 The clinical features and survival times of patients with unknown primary carcinoma (UPC) are heterogeneous. Therefore, the goals of this study were to apply a novel analytical method to UPC patients to: (a) identify novel prognostic factors; (b) explore t ... Link to item Cite

Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.

Journal Article Oncogene · August 12, 1999 The Rel/NF-kappaB transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-kappaB transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We rep ... Full text Link to item Cite

Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Journal Article Int J Radiat Oncol Biol Phys · July 15, 1999 PURPOSE: To evaluate the rates of tumor downstaging after preoperative chemoradiation for locally advanced rectal cancer. MATERIALS AND METHODS: Preoperative chemoradiotherapy (CTX/XRT) that delivered 45 Gy in 25 fractions over 5 weeks with continuous infu ... Full text Link to item Cite

Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.

Journal Article Anticancer Drugs · July 1999 A clinical trial regimen modulating 5-fluorouracil (5-FU) with both folinic acid (FA) and recombinant alpha-2a-interferon (ralpha-2a-IFN) was noted to have a response rate of 54% and median survival of 16.3 months (Grem et al., J Clin Oncol 1993, 11: 1737- ... Full text Link to item Cite

Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.

Conference Ann N Y Acad Sci · June 30, 1999 The tumor suppressor gene deleted in pancreatic cancer locus 4 (Smad4/DPC4) is inactivated in about 50% of pancreatic adenocarcinomas. The role of DPC4 in the transforming growth factor-beta (TGF-beta) receptor-mediated signal transduction cascade in human ... Full text Link to item Cite

Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.

Journal Article Radiother Oncol · May 1999 BACKGROUND AND PURPOSE: To evaluate the influence of response to preoperative infusional chemoradiation on outcome parameters among patients with locally advanced rectal cancer. MATERIALS AND METHODS: Preoperative chemoradiotherapy, 45 Gy in 25 fractions o ... Full text Link to item Cite

Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis.

Journal Article J Gastrointest Surg · 1999 Intraoperative assessment is inaccurate in defining the relationship of a pancreatic head neoplasm to adjacent vascular structures. We evaluated the ability of preoperative contrast-enhanced CT to predict the need for vascular resection during pancreaticod ... Full text Link to item Cite

Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma.

Journal Article Clin Cancer Res · January 1999 We examined the expression level of several genes that regulate distinct steps of metastasis in formalin-fixed, paraffin-embedded, archival specimens of primary human pancreatic carcinomas from patients undergoing curative surgery. The expression of epider ... Link to item Cite

The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Journal Article Clin Cancer Res · January 1999 Pancreatic adenocarcinoma is a leading cause of adult cancer mortality in the United States. Recent studies have revealed that point mutation of the K-ras oncogene is a common event in pancreatic cancer, and oncogenesis mediated by Ras may also involve act ... Link to item Cite

Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.

Journal Article J Gastrointest Surg · 1999 The p53 tumor suppressor gene and the Bcl-2 proto-oncogene regulate cell cycle progression and apoptosis. We evaluated the expression of these molecular markers with standard pathologic prognostic variables in patients who received multimodality therapy fo ... Full text Link to item Cite

Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines.

Journal Article Clin Cancer Res · December 1998 Epithelial ovarian cancer is a major cause of cancer-related mortality in women, making the search for new treatment modalities essential. Sodium phenylacetate (NaPa), a phenylalanine derivative, has been shown to induce cytostasis and differentiation by i ... Link to item Cite

Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents

Journal Article Gastrointestinal Endoscopy · December 1, 1998 Introduction: The application of expandable stents, commonly used for biliary and esophageal strictures is gaining acceptance in the treatment of gastric outlet obstruction. We report here our experience with 18 patients with malignant gastric outlet and d ... Cite

Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas.

Journal Article Surgery · December 1998 BACKGROUND: Fine-needle aspiration biopsy to identify adrenal metastasis from an occult primary malignancy has been recommended as part of the evaluation of the patient who presents with an incidentally discovered adrenal mass. This recommendation was asse ... Full text Link to item Cite

Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.

Journal Article J Clin Oncol · December 1998 PURPOSE: To evaluate the toxicities, radiographic and pathologic responses, and event-free outcomes with combined modality treatment that involves preoperative rapid-fractionation chemoradiation, pancreaticoduodenectomy, and electron-beam intraoperative ra ... Full text Link to item Cite

Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments].

Journal Article Ann Surg Oncol · December 1998 BACKGROUND: The p53 tumor suppressor gene is mutated in up to 70% of pancreatic adenocarcinomas. We determined the effect of reintroduction of the wild-type p53 gene on proliferation and apoptosis in human pancreatic cancer cells using an adenoviral vector ... Full text Link to item Cite

Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.

Conference Front Biosci · November 1, 1998 Adjuvant 5-fluorouracil and concurrent radiation may improve survival following complete surgical resection in patients with pancreatic adenocarcinoma. However, the morbidity and prolonged recovery associated with pancreaticoduodenectomy frequently prevent ... Full text Link to item Cite

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.

Journal Article Ann Oncol · September 1998 BACKGROUND: The long intracellular half-life of gemcitabine's active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), suggested that small increases in peak intracellular dFdCTP levels would have a profound effect on its intracellular area under th ... Full text Link to item Cite

Cell cycle regulation of human pancreatic cancer by tamoxifen.

Journal Article Ann Surg Oncol · June 1998 BACKGROUND: Clinical trials have suggested a survival advantage for selected patients with metastatic pancreatic cancer treated with tamoxifen. We sought to identify the molecular mechanism by which tamoxifen inhibits human pancreatic cancer cell (HPCC) gr ... Full text Link to item Cite

Unknown primary tumors metastatic to liver.

Journal Article J Clin Oncol · June 1998 PURPOSE: The objectives of this study were to identify prognostic factors for unknown primary tumor (UPT) patients with hepatic metastases, determine the common primary tumors identified, assess the yield of specific diagnostic studies, and evaluate the im ... Full text Link to item Cite

Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan.

Journal Article Ann Oncol · February 1998 Women with isolated metastatic carcinoma or adenocarcinoma involving axillary lymph nodes are a well-recognized group of unknown primary carcinoma (UPC) patients with a favorable prognosis. This group of patients are generally treated based on the assumpti ... Full text Link to item Cite

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.

Journal Article Invest New Drugs · 1998 9-Aminocamptothecin (9-AC) is a camptothecin derivative with broad antitumor activity in preclinical studies. Prior investigations suggested that prolonged maintenance of 9-AC lactone plasma concentrations above 10 nmol/l and frequent administration of the ... Full text Link to item Cite

Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.

Journal Article Surg Oncol Clin N Am · January 1998 Pancreaticoduodenectomy is performed on carefully selected patients as part of a protocol-based clinical research program emphasizing the importance of multimodality management for patients with potentially resectable adenocarcinoma of the pancreatic head. ... Link to item Cite

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Journal Article Hepatogastroenterology · 1998 The goal of multimodality therapy for localized pancreatic cancer is to maximize local-regional disease control and patient survival. In contrast to surgery for other solid tumors, prolonged recovery following pancreaticoduodenectomy may prevent the timely ... Link to item Cite

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial.

Journal Article Cancer Chemother Pharmacol · 1998 A highly sensitive and specific assay for the quantitation of the anticancer agent dolastatin-10 (DOL-10) in human plasma is described. The method was based on the use of electrospray ionization-high-performance liquid chromatography/mass spectrometry (ESP ... Full text Link to item Cite

Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas.

Journal Article J Hepatobiliary Pancreat Surg · 1998 Patients who undergo pancreaticoduodenectomy alone for adenocarcinoma of the pancreatic head or uncinate process have a median survival of 12 months, and a high incidence of local tumor recurrence (50%-80%) due to the common finding of positive margins fol ... Full text Link to item Cite

DNA adducts in human pancreatic tissues and their potential role in carcinogenesis.

Journal Article Cancer Res · January 1, 1998 Pancreas cancer is the fourth and fifth leading cause of cancer death for men and women, respectively, in the United States. Although the etiology of this cancer is poorly understood, smoking and dietary fat have been implicated by epidemiological studies. ... Link to item Cite

Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.

Journal Article Frontiers in bioscience : a journal and virtual library · 1998 Adjuvant 5-fluorouracil and concurrent radiation may improve survival following complete surgical resection in patients with pancreatic adenocarcinoma. However, the morbidity and prolonged recovery associated with pancreaticoduodenectomy frequently prevent ... Cite

Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.

Journal Article Am J Clin Oncol · December 1997 CI-980 (NSC 370147)--a synthetic mitotic inhibitor that binds to tubulin at the colchicine binding site--has significant activity against a broad spectrum of tumor models and greater in vitro cytotoxicity when given over > 24 hours than 4 hours or less. Ph ... Full text Link to item Cite

Docetaxel enhances tumor radioresponse in vivo.

Journal Article Clin Cancer Res · December 1997 Although the radiosensitizing potential of paclitaxel has been investigated extensively in cancer treatment, a sister taxane, docetaxel, has been studied rarely. We investigated the ability of docetaxel to enhance in vivo tumor radioresponse and influence ... Link to item Cite

The Michael/Moore Article Reviewed

Journal Article ONCOLOGY · December 1, 1997 Cite

NCCN practice guidelines for pancreatic cancer.

Journal Article Oncology (Williston Park) · November 1997 Link to item Cite

Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.

Journal Article Cancer Res · October 1, 1997 The aim of this study was to determine the antiproliferative activity of sodium phenylacetate (NaPa) against ovarian carcinoma cell lines. NaPa induced a dose-dependent inhibition (IC50 from 12 mM to >20 mM) of all ovarian carcinoma cell lines, although th ... Link to item Cite

Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.

Journal Article Cancer Res · September 15, 1997 The tumor suppressor gene deleted in pancreatic cancer locus 4 (DPC4) is inactivated in about 50% of pancreatic adenocarcinomas. DPC4 was found to be homologous to Smad4 and may function as a transcription factor in the transforming growth factor beta (TGF ... Link to item Cite

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.

Journal Article J Clin Oncol · August 1997 PURPOSE: The camptothecin derivative irinotecan has demonstrated clinical activity in metastatic colorectal carcinoma in both chemotherapy-naive and fluorouracil-refractory patients. 9-Aminocamptothecin (9-AC; NSC 603071), another camptothecin derivative, ... Full text Link to item Cite

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

Journal Article J Clin Oncol · May 1997 PURPOSE: The objectives of this study were to assess clinical outcomes and prognostic factors in unselected, consecutive patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA). PATIENTS AND METHODS: The 1,400 pati ... Full text Link to item Cite

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Journal Article J Clin Oncol · March 1997 PURPOSE: The effects of preoperative versus postoperative fluorouracil (5-FU)-based chemotherapy and irradiation on treatment toxicity, duration of treatment, tumor recurrence, and survival were compared in patients who underwent potentially curative thera ... Full text Link to item Cite

Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer.

Journal Article Anticancer Res · 1997 BACKGROUND: Because treatment of advanced pancreatic cancer is often unsuccessful, early detection is important. Codon 12 c-Ki-ras mutations have been found in 80-90% of pancreatic cancer cases and are a potential early marker for pancreatic cancer, but ob ... Link to item Cite

Endoscopic management of biliary tract cancer with the wallstent: Experience in 121 patients

Journal Article Gastrointestinal Endoscopy · January 1, 1997 The treatment of choice for malignant biliary strictures is endoscopic stenting, either plastic or metallic. Eventhough metallic stents have shown a longer patency rate and easier placement, their use is still not widely accepted. We report our experience ... Full text Cite

Comparison between metastatic vs primary biliary tract cancer in their response to the wallstent

Journal Article Gastrointestinal Endoscopy · January 1, 1997 The treatment of choice for malignant biliary strictures is endoscopic stenting, either plastic or expandable. Data regarding the outcome after stenting for biliary strictures are limited regarding metastatic (M) vs primary (P) disease. We report our exper ... Full text Cite

Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer

Journal Article Anticancer Research · 1997 Background: Because treatment of advanced pancreatic cancer is often unsuccessful, early detection is important. Codon 12 c-Ki-ras mutations have been found in 80-90% of pancreatic cancer cases and are a potential early marker for pancreatic cancer, but ob ... Cite

Docetaxel enhances tumor radioresponse in vivo

Journal Article Clinical Cancer Research · 1997 Although the radiosensitizing potential of paclitaxel has been investigated extensively in cancer treatment, a sister taxane, docetaxel, has been studied rarely. We investigated the ability of docetaxel to enhance in vivo tumor radioresponse and influence ... Cite

Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies

Journal Article GI Cancer · December 1, 1996 Pancreatic cancer is the fourth leading cause of adult cancer mortality. The etiology of cancer of the pancreas remains a mystery despite the implication of various agents such as coffee, alcohol and cigarettes. Adenocarcinoma of the pancreas most commonly ... Cite

bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.

Journal Article Clin Cancer Res · December 1996 The bcl-2 proto-oncogene and the p53 tumor suppressor gene are important determinants of tumor cell susceptibility to apoptosis. bcl-2 and mutant p53 proteins inhibit apoptosis in vitro and can provide prognostic information in certain tumor types. We anal ... Link to item Cite

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.

Journal Article Blood · October 1, 1996 The aim of this study was to evaluate the activity of topotecan in patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Forty-seven patients with a diagnosis of MDS (n = 22) or CMML (n = 25) were treated. The median age ... Link to item Cite

Phase I studies with the novel nucleoside analog gemcitabine.

Journal Article Semin Oncol · October 1996 Extensive data generated from early phase I trials have demonstrated important schedule-dependent differences in gemcitabine's toxicity profile and activity. Frequent drug administration produced a high incidence of toxicities: in the daily schedule, flu-l ... Link to item Cite

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.

Journal Article Clin Cancer Res · September 1996 Topotecan, a semisynthetic water-soluble analogue of camptothecin, inhibits human topoisomerase I (topo I). We performed a Phase I clinical and plasma pharmacological study of topotecan administered by 24-h continuous infusion without and with granulocyte ... Link to item Cite

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma.

Journal Article Cancer · August 1, 1996 BACKGROUND: Using classical endpoints, such as response rate and survival, as the sole measures of benefit, little progress has been made in the treatment of advanced pancreatic carcinoma in the past 30 years. We challenge the assumption that response rate ... Full text Link to item Cite

The need for standardized pathologic staging of pancreaticoduodenectomy specimens.

Journal Article Pancreas · May 1996 A standardized method for pathologic evaluation and staging of pancreaticoduodenectomy (PD) specimens is critical for accurate reporting of the number and location of lymph nodes and margins of resection. We examined the impact of standardized pathologic e ... Full text Link to item Cite

Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells.

Journal Article Int J Pancreatol · February 1996 CONCLUSION: We established a new human pancreatic adenocarcinoma cell line, MDAPanc-28. Studies on this new line indicate that it expressed both acinar and ductal gene products suggesting that the patterns of gene expression in the pancreatic adenocarcinom ... Full text Link to item Cite

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.

Journal Article Am J Surg · January 1996 BACKGROUND: Local recurrence in the bed of the resected pancreas is the most common site of tumor recurrence following a standard pancreaticoduodenectomy (PD) for adenocarcinoma of the pancreatic head. In an attempt to improve local and regional disease co ... Full text Link to item Cite

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer.

Journal Article Invest New Drugs · 1996 BACKGROUND: Currently available therapies for advanced pancreatic cancer offer only palliative benefits, and patients with this disease have a poor prognosis. We undertook a phase II trial of ZD1694 (Tomudex), a quinazoline folate analogue that is a potent ... Full text Link to item Cite

Phase I studies with the novel nucleoside analog gemcitabine

Journal Article Seminars in Oncology · 1996 Extensive data generated from early phase I trials have demonstrated important schedule-dependent differences in gemcitabine's toxicity profile and activity. Frequent drug administration produced a high incidence of toxicities; in the daily schedule, flu-l ... Cite

Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma.

Journal Article Am J Clin Oncol · December 1995 The combination of interferons (IFNs) and retinoids in antineoplastic therapy is based upon preclinical, in vitro, and in vivo observations. Retinoid-IFN combinations have shown significant antitumor activity against advanced cutaneous and cervical squamou ... Full text Link to item Cite

Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.

Journal Article Cancer · November 15, 1995 BACKGROUND: Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil (5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest acti ... Full text Link to item Cite

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.

Journal Article Int J Radiat Oncol Biol Phys · November 1, 1995 PURPOSE: In an effort to reduce relapse in the liver and improve survival in patients with potentially resectable adenocarcinoma of the pancreatic head, we combined whole-liver irradiation with our standard preoperative chemoradiation regimen. METHODS AND ... Full text Link to item Cite

Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms.

Journal Article J R Coll Surg Edinb · October 1995 The multimodality treatment of adenocarcinoma of the pancreatic head has been shown to improve survival compared with surgery alone. The delivery of chemotherapy and radiation therapy (chemoradiation) before rather than after pancreaticoduodenectomy ensure ... Link to item Cite

Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.

Journal Article Am J Clin Oncol · October 1995 Phase II trials of the novel biologic combination isotretinoin (13-cis-retinoic aid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinoma of the skin and cervix. Because this combi ... Full text Link to item Cite

Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head.

Journal Article Surgery · September 1995 BACKGROUND: Recurrence in the peritoneum occurs in up to 50% of patients after a potentially curative pancreaticoduodenectomy. Previous authors have implicated preoperative fine-needle aspiration (FNA) as a cause of intraperitoneal tumor dissemination, alt ... Full text Link to item Cite

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

Journal Article J Clin Oncol · August 1995 PURPOSE: Diagnostic strategies designed to identify the underlying primary malignancies in patients with unknown primary tumors (UPTs) have relied on retrospective analyses. We analyzed 879 consecutive patients referred with suspected UPTs to determine the ... Full text Link to item Cite

Phase I and II trials of a laboratory-derived synergistic combination of cisplatin and 2'-deoxy-5-azacytidine

Journal Article International Journal of Oncology · January 1, 1995 Phase I and phase II trials of a laboratory-derived synergistic combination of cisplatin (cDDP) and 2'-deoxy-5-azacytidine (5-aza-CdR) were conducted. The maximum tolerated doses (MTDs) were 50 mg/m2 of 5-aza-CdR and 75 mg/m2 of cDDP. A response rate of 17 ... Cite

A pilot study of paclitaxel in previously treated patients with metastatic unknown primary carcinomas

Journal Article Oncology Reports · January 1, 1995 We enrolled 12 patients in a pilot phase II study to evaluate the efficacy and toxicity of paclitaxel as a single agent in the salvage treatment of patients with metastatic unknown primary carcinoma (UPC). Patients were given 175 mg/m2 of paclitaxel as a t ... Full text Cite

Preoperative chemoradiation for adenocarcinoma of the pancreas: M.D. Anderson experience

Journal Article Seminars in Surgical Oncology · January 1, 1995 Pancreatic cancer remains the fourth leading cause of cancer‐related deaths in adults in this country. Its etiology is unknown, and there is currently no effective method of early diagnosis. Although this article wil focus on the proper management of patie ... Full text Cite

A phase I clinical trial of a protracted continuous infusion of 5-fluorouracil with oral folinic acid in patients with unresectable adenocarcinoma of the colon or rectum

Journal Article International Journal of Oncology · January 1, 1995 Studies of the mechanism of action of 5-fluorouracil (5-FU) suggest that maximal inhibition of the target enzyme thymidylate synthase can be achieved with a protracted infusion of 5-FU and oral leucovorin. We report the results of a phase I study in which ... Full text Cite

Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

Journal Article Oncology Reports · January 1, 1995 Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5 ... Full text Cite

Novel diagnostic and therapeutic approaches to pancreatic cancer

Journal Article Cancer Bulletin · December 1, 1994 PANCREATIC CANCER is highly resistant to therapy. The traditional treatment modalities of surgery, radiotherapy, and chemotherapy, singly or in combination, have made little impact on this disease; however, basic scientific research has improved our unders ... Cite

Preoperative chemoradiotherapy, pancreaticoduodenectomy, and external- beam intraoperative radiotherapy for pancreatic adenocarcinoma: The M.D. Anderson experience

Journal Article Cancer Bulletin · December 1, 1994 FOR PATIENTS undergoing potentially curative pancreaticoduodenectomy, reported 5-year survival rates range from 10%-25%. Recurrence in the bed of the resected pancreas has traditionally represented the most common initial site of treatment failure. In this ... Cite

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.

Journal Article J Clin Oncol · November 1994 PURPOSE: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration (UFT; Taiho Pharmaceutical Ltd, Tokyo, Japan) plus oral calcium leucovorin in the treatment of patients with advanced colorectal carcinoma. PATI ... Full text Link to item Cite

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.

Journal Article J Clin Oncol · June 1994 PURPOSE: To evaluate the natural history, validate previous observations, and identify prognostic factors in patients with unknown primary carcinoma (UPC). PATIENTS AND METHODS: Nine hundred twenty-seven consecutive patients referred to the M.D. Anderson C ... Full text Link to item Cite

Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.

Journal Article Ann Oncol · May 1994 BACKGROUND: Docetaxel (Taxotere) is prepared from a noncytotoxic precursor extracted from the needles of the Taxus baccata. Preclinical investigations have demonstrated that docetaxel is very active in colon adenocarcinoma murine models. Phase I studies re ... Full text Link to item Cite

The Bird's Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies.

Journal Article Am J Clin Oncol · April 1994 Thromboembolic complications are common in patients with advanced malignancies. For these patients anticoagulation with warfarin is often complicated by severe bleeding. For this reason we evaluated the safety and efficacy of the Bird's Nest Filter, a new ... Link to item Cite

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.

Journal Article Ann Oncol · March 1994 BACKGROUND: The methotrexate analogue 10-ethyl-10-deazaaminopterin (10-EdAM, or edatrexate) has shown antitumor activity in preclinical testing and clinical studies of patients with breast, lung and head and neck carcinomas. A phase II study was conducted ... Full text Link to item Cite

Phase II trial of intravenous melphalan in advanced colorectal carcinoma.

Journal Article Invest New Drugs · 1994 BACKGROUND: Relatively few studies have examined the activity of alkylating agents in the treatment of advanced colorectal adenocarcinoma. Recent reports have suggested possible therapeutic activity for high-dose intravenous melphalan administered with aut ... Full text Link to item Cite

Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.

Journal Article Am J Surg · January 1994 A prospective diagnostic study was designed to determine the ability of thin-section contrast-enhanced computed tomography (CT) to predict the resectability of malignant neoplasms of the pancreatic head. Patients with a presumed resectable pancreatic neopl ... Full text Link to item Cite

Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.

Journal Article Anticancer Res · 1994 The sequential administration of 2'-deoxy-5-azacytidine (DAC) and cisplatin frequently results in synergistic cytotoxicity against human cancer cell lines (Frost P, et al Cancer Res 50:4572-4577, 1990) including the cisplatin resistant HEY ovarian cancer c ... Link to item Cite

Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines

Journal Article Anticancer Research · 1994 The sequential administration of 2'-deoxy-5-azacytidine (DAC) and cisplatin frequently results in synergistic cytotoxicity against human cancer cell lines including the cisplatin resistant resistant HEY ovarian cancer cell line. In this series of in vitro ... Cite

A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.

Journal Article Cancer · November 1, 1993 BACKGROUND: Mitoxantrone is an anthraquinone derivative that has demonstrated encouraging preclinical and clinical activity against a variety of human carcinoma cell lines and malignancies. Three Phase II studies of systemically administered mitoxantrone i ... Full text Link to item Cite

The biology of unknown primary tumors.

Journal Article Semin Oncol · June 1993 Link to item Cite

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.

Journal Article Invest New Drugs · February 1993 Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at ... Full text Link to item Cite

2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

Journal Article Br J Cancer · February 1993 The chemotherapeutic agents 2'-deoxy-5-azacytidine (DAC) and cisplatin (cDDP) have been shown in vitro to be synergystic in their cytotoxicity toward human tumour cells. We have investigated possible molecular mechanisms underlying this synergy using the p ... Full text Link to item Cite

p53 gene mutation spectrum in human unknown primary tumors.

Journal Article Anticancer Res · 1993 Mutations affecting the p53 gene are associated with many human malignancies, but little is known about changes in p53 in unknown primary tumors (UPTs), which are characterized as tumors with advanced stages of malignancy. We therefore investigated the fre ... Link to item Cite

p53 Gene mutation spectrum in human unknown primary tumors

Journal Article Anticancer Research · 1993 Mutations affecting the p53 gene are associated with many human malignacies but little is known about changes in p53 in unknown primary tumors (UPTs) which are characterized as tumors with advanced stages of malignancy. We therefore investigated the freque ... Cite

Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.

Journal Article Am J Clin Oncol · December 1992 A total of 48 patients with measurable advanced gastric adenocarcinoma (n = 16) or adenocarcinoma of the exocrine pancreas (n = 32) were prospectively treated with iproplatin at a starting dose of 270 mg/m2 intravenously over 2 hours. The dose was repeated ... Link to item Cite

Phase II study of gemcitabine in advanced colorectal adenocarcinoma.

Journal Article Invest New Drugs · November 1992 A phase II trial of gemcitabine (difluorodeoxycytidine) was conducted in 14 patients with advanced colorectal adenocarcinoma. Gemcitabine was administered intravenously over 30 minutes at weekly intervals for 3 consecutive weeks each month. The starting do ... Full text Link to item Cite

Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.

Journal Article Cancer · October 15, 1992 BACKGROUND: Based on initial encouraging results of the combination of 5-fluorouracil (5-FU) with recombinant alpha-2a-interferon (r alpha-2a-IFN) in the treatment of advanced colorectal carcinomas, a clinical trial was conducted using 5-FU with r alpha-2a ... Full text Link to item Cite

Phase II study of didemnin B in advanced colorectal cancer.

Journal Article Invest New Drugs · August 1992 Didemnin B is a depsipeptide derived from a Caribbean tunicate (sea squirt) that has demonstrated antineoplastic activity against a variety of murine tumor models, including the L1210 and P388 leukemia, the B16 melanoma, and M5076 sarcoma cell lines. Based ... Full text Link to item Cite

Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.

Journal Article Cancer Res · April 15, 1992 Synergy, when it can be convincingly established, is an effective strategy for the development of novel drug combinations. We have evaluated the interaction between 2'-deoxy-5-azacytidine (DAC) and 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) b ... Link to item Cite

Phase II trial of fazarabine in advanced colorectal carcinoma.

Journal Article Invest New Drugs · April 1992 A total of 15 patients with measurable advanced colorectal adenocarcinoma were prospectively treated with fazarabine (Ara-AC), reconstituted in dimethyl sulfoxide, and administered at a starting dose of 48 mg/m2/day as a continuous intravenous infusion for ... Full text Link to item Cite

Cognitive functioning in cancer patients: effect of previous treatment.

Journal Article Neurology · February 1992 Neuropsychological analysis of 47 cancer patients with widely metastatic disease and significant previous treatment indicated that 34% had cognitive deficits. Previous treatment with biologic response modifiers was associated with a 53% frequency of cognit ... Full text Link to item Cite

Unknown primary tumors.

Journal Article Curr Opin Oncol · February 1992 Link to item Cite

Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Journal Article Cancer Chemother Pharmacol · 1992 2'-Deoxy-5-azacytidine (5-aza-CdR) and cisplatin interact to produce synergistic cytotoxicity against many human tumor cell lines. Preliminary experiments designed to explore the mechanism of this synergy suggested a poor correlation between synergy and th ... Full text Link to item Cite

A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer.

Journal Article Pancreas · 1992 MK-329 is a nonpeptidal, highly specific cholecystokinin (CCK) receptor antagonist, with affinity for pancreatic and gallbladder CCK receptors similar to CCK itself. MK-329 and its progenitor, asperlicin, can inhibit the growth of CCK receptor-positive hum ... Full text Link to item Cite

Adenocarcinoma of the liver without a detectable primary.

Journal Article Hosp Pract (Off Ed) · December 15, 1991 Full text Link to item Cite

Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas.

Journal Article Invest New Drugs · November 1991 In a phase II study, 32 patients with advanced pancreatic carcinoma were treated with intravenous 6-thioguanine. A 30-min infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the course being repeated every 5 weeks. A me ... Full text Link to item Cite

Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Journal Article Invest New Drugs · November 1991 To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 ... Full text Link to item Cite

Metastatic adenocarcinoma to the neck from an unknown primary source.

Journal Article Am J Surg · October 1991 We report a retrospective review of 223 patients who presented to the Department of Head and Neck Surgery from 1970 through 1987 with a diagnosis of metastatic adenocarcinoma of unknown primary origin. Multivariate analysis was performed using the followin ... Full text Link to item Cite

Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma.

Journal Article Invest New Drugs · August 1991 In a phase II study, 18 patients with advanced gastric carcinoma were treated with intravenous 6-thioguanine. A 30-minute infusion of 55 mg/m2 (starting dose) was administered once a day for 5 consecutive days, the courses being repeated every 5 weeks. A m ... Full text Link to item Cite

Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.

Journal Article Ann Oncol · July 1991 We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin. Of the thirty-six evaluable patients (21 ... Full text Link to item Cite

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Journal Article J Clin Oncol · March 1991 A novel deoxycytidine analog, gemcitabine (2',2'-difluorodeoxycytidine [dFdC]), has been studied in a phase I clinical and pharmacology trial. Doses ranging from 10 to 1,000 mg/m2 were administered over 30 minutes weekly times 3 weeks every 4 weeks. The ma ... Full text Link to item Cite

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.

Journal Article Cancer Chemother Pharmacol · 1991 The plasma and cellular pharmacology of 2',2'-difluorodeoxycytidine (dFdC, Gemcitabine) was studied during a phase I trial. The steady-state concentration of dFdC in plasma was directly proportional to the dFdC dose, which ranged between 53 and 1,000 mg/m2 ... Full text Link to item Cite

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.

Journal Article J Clin Oncol · December 1990 We conducted a phase II clinical trial of fluorouracil (5FU) and recombinant interferon alfa-2a (rIFN alpha-2a) in 52 previously untreated patients with bidimensionally measurable metastatic colorectal cancer. During week 1, 5FU was administered as a conti ... Full text Link to item Cite

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

Journal Article Cancer Res · November 1, 1990 The objective of this study was to determine the dose rate of 2',2'-difluorodeoxycytidine (dFdC) that maximizes the accumulation of the active 5'-triphosphate (dFdCTP) in circulating leukemia cells during therapy. The investigational approach was to evalua ... Link to item Cite

A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.

Journal Article J Biol Response Mod · October 1990 Recombinant human tumor necrosis factor and recombinant human interferon-gamma are two representatives of a novel class of antineoplastic agents. Evaluation of these agents in vitro has suggested that the combination would be more effective than either age ... Link to item Cite

Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.

Journal Article Cancer Res · August 1, 1990 The combined use of 2'-deoxy-5-azacytidine with cisplatin or 4-hydroperoxycyclophosphamide in vitro frequently resulted in synergistic cytotoxicity against a panel of six human cell lines. This enhanced cell killing occurred at drug concentrations that are ... Link to item Cite

Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.

Journal Article J Clin Oncol · July 1990 Thirty-five consecutive patients with resectable adenocarcinoma of the esophagus or gastroesophageal junction were treated with two preoperative and three or four postoperative chemotherapy courses consisting of etoposide, fluorouracil, and cisplatin (EFP) ... Full text Link to item Cite

A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.

Journal Article Cancer Invest · 1990 Thirty patients with measurable metastatic colorectal carcinoma who had not received prior systemic therapy for advanced disease were treated with trimetrexate, a methotrexate analog. Trimetrexate was administered at a median daily dose of 15 mg/m2 (range, ... Full text Link to item Cite

Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.

Journal Article Cancer Chemother Pharmacol · 1990 We report the results of a phase I study of intravenously administered cisplatin, 5-fluorouracil and high-dose folinic acid. This trial was designed to exploit potential biochemical interactions between these three agents. The maximum tolerated doses were ... Full text Link to item Cite

Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.

Journal Article Cancer Chemother Pharmacol · 1990 A total of 32 evaluable patients with measurable advanced colorectal carcinoma were treated with continuous-infusion alpha-difluoromethylornithine (DFMO) at a median daily dose of 8 g/m2 (range, 6-14 g/m2). DFMO was infused over 24 h daily for 28 days, fol ... Full text Link to item Cite

Current status of chemotherapy for colorectal cancer

Journal Article Drug Therapy · December 1, 1989 Cite

Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.

Journal Article Cancer Res · July 15, 1989 Recombinant human gamma-interferon and recombinant human tumor necrosis factor are two representatives of a new class of antineoplastic agents. In vitro studies have suggested synergistic cytotoxic activities when the agents are combined. We report a phase ... Link to item Cite

Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.

Journal Article Invest New Drugs · July 1989 FMAU (1-[2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl]-5-methyluracil) a newly synthesized fluorinated nucleoside, has potent in vitro antiviral and antileukemic activity and is active in murine leukemia lines resistant to cytosine arabinoside. In the init ... Full text Link to item Cite

Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.

Journal Article J Biol Response Mod · April 1989 Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patient ... Link to item Cite

Treatment of advanced colorectal cancer.

Journal Article Hematol Oncol Clin North Am · March 1989 This article delineates the current status of clinical research into the chemotherapeutic treatment of advanced colorectal cancer. The data reviewed indicate that, despite an extensive series of trials, no new agents with significant activity have been ide ... Link to item Cite

Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.

Journal Article Cancer Chemother Pharmacol · 1989 The purpose of this study was to evaluate the response rate, methotrexate plasma levels, and toxicity of a three-drug regimen in patients with gastric carcinoma. A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated wit ... Full text Link to item Cite

Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.

Journal Article J Clin Oncol · November 1988 Ifosfamide, an analogue of cyclophosphamide, has therapeutic activity against a wide variety of human malignancies. In a phase II trial in carcinoma of the pancreas, we treated 31 patients who had not received prior chemotherapy with a median ifosfamide do ... Full text Link to item Cite

Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.

Journal Article Invest New Drugs · April 1988 For phase II studies in patients with solid tumors, the National Cancer Institute recommended that the starting dose of fludarabine phosphate be 20 mg/m2/day as a short intravenous infusion for 5 days every 21 days. Twenty-one patients with untreated, adva ... Full text Link to item Cite

Recent approaches to the systemic therapy of advanced colorectal carcinoma

Journal Article Cancer Bulletin · January 1, 1988 Cite

Role of computerized cranial tomography in the staging of small cell carcinoma of the lung.

Journal Article Cancer Treat Rep · November 1984 Fifty-five patients with small cell lung cancer underwent computerized cranial tomography (CCT) and a complete neurologic examination as part of their staging work-up. Fifteen patients (27%) had evidence of brain metastases detected by CCT at the time of d ... Link to item Cite

Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections.

Journal Article Am J Med · April 1983 In a prospective, randomized, double-blind trial, a regimen of 250 mg of moxalactam every 12 hours was compared with 1.0 mg/kg of tobramycin every eight hours in the treatment of urinary tract infections. One hundred and eleven patients were entered into t ... Full text Link to item Cite

Postural hypotension.

Journal Article Johns Hopkins Med J · March 1981 Link to item Cite

Separation of paprika pigments: An introductory t/c experiment

Journal Article Journal of Chemical Education · January 1, 1976 Full text Cite